<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6214495</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0204371</article-id><article-id pub-id-type="publisher-id">PONE-D-18-26168</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Cell biology</subject><subj-group><subject>Chromosome biology</subject><subj-group><subject>Chromatin</subject><subj-group><subject>Chromatin modification</subject><subj-group><subject>DNA methylation</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Epigenetics</subject><subj-group><subject>Chromatin</subject><subj-group><subject>Chromatin modification</subject><subj-group><subject>DNA methylation</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Gene expression</subject><subj-group><subject>Chromatin</subject><subj-group><subject>Chromatin modification</subject><subj-group><subject>DNA methylation</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>DNA</subject><subj-group><subject>DNA modification</subject><subj-group><subject>DNA methylation</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Nucleic acids</subject><subj-group><subject>DNA</subject><subj-group><subject>DNA modification</subject><subj-group><subject>DNA methylation</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Epigenetics</subject><subj-group><subject>DNA modification</subject><subj-group><subject>DNA methylation</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Gene expression</subject><subj-group><subject>DNA modification</subject><subj-group><subject>DNA methylation</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and Neoplasms</subject><subj-group><subject>Genitourinary Tract Tumors</subject><subj-group><subject>Prostate Cancer</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Urology</subject><subj-group><subject>Prostate Diseases</subject><subj-group><subject>Prostate Cancer</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Diagnostic Medicine</subject><subj-group><subject>Cancer Detection and Diagnosis</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancer Detection and Diagnosis</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Chemical Reactions</subject><subj-group><subject>Methylation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and Neoplasms</subject><subj-group><subject>Carcinomas</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Nephrology</subject><subj-group><subject>Renal Cancer</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Exocrine Glands</subject><subj-group><subject>Prostate Gland</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Exocrine Glands</subject><subj-group><subject>Prostate Gland</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Renal System</subject><subj-group><subject>Bladder</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Renal System</subject><subj-group><subject>Bladder</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>LogLoss-BERAF: An ensemble-based machine learning model for constructing highly accurate diagnostic sets of methylation sites accounting for heterogeneity in prostate cancer</article-title><alt-title alt-title-type="running-head">Diagnostic model accounting for heterogeneity in prostate cancer</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-7136-3894</contrib-id><name><surname>Babalyan</surname><given-names>K.</given-names></name><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="aff" rid="aff003"><sup>3</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib><contrib contrib-type="author"><name><surname>Sultanov</surname><given-names>R.</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Methodology</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-6314-4883</contrib-id><name><surname>Generozov</surname><given-names>E.</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-3208-9719</contrib-id><name><surname>Sharova</surname><given-names>E.</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Supervision</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kostryukova</surname><given-names>E.</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Supervision</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Larin</surname><given-names>A.</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-4993-9492</contrib-id><name><surname>Kanygina</surname><given-names>A.</given-names></name><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Govorun</surname><given-names>V.</given-names></name><role content-type="http://credit.casrai.org/">Project administration</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-2323-1859</contrib-id><name><surname>Arapidi</surname><given-names>G.</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow, Russian Federation</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Moscow Institute of Physics and Technology (State University), Dolgoprudny, Moscow Region, Russian Federation</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, Russian Federation</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Elofsson</surname><given-names>Arne</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>Stockholm University, SWEDEN</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><corresp id="cor001">* E-mail: <email>babalyan@phystech.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>2</day><month>11</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>13</volume><issue>11</issue><elocation-id>e0204371</elocation-id><history><date date-type="received"><day>31</day><month>1</month><year>2018</year></date><date date-type="accepted"><day>6</day><month>9</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; 2018 Babalyan et al</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Babalyan et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0204371.pdf"/><abstract><p>Although modern methods of whole genome DNA methylation analysis have a wide range of applications, they are not suitable for clinical diagnostics due to their high cost and complexity and due to the large amount of sample DNA required for the analysis. Therefore, it is crucial to be able to identify a relatively small number of methylation sites that provide high precision and sensitivity for the diagnosis of pathological states. We propose an algorithm for constructing limited subsamples from high-dimensional data to form diagnostic panels. We have developed a tool that utilizes different methods of selection to find an optimal, minimum necessary combination of factors using cross-entropy loss metrics (LogLoss) to identify a subset of methylation sites. We show that the algorithm can work effectively with different genome methylation patterns using ensemble-based machine learning methods. Algorithm efficiency, precision and robustness were evaluated using five genome-wide DNA methylation datasets (totaling 626 samples), and each dataset was classified into tumor and non-tumor samples. The algorithm produced an AUC of 0.97 (95% CI: 0.94&#x02013;0.99, 9 sites) for prostate adenocarcinoma and an AUC of 1.0 (from 2 to 6 sites) for urothelial bladder carcinoma, two types of kidney carcinoma and colorectal carcinoma. For prostate adenocarcinoma we showed that identified differential variability methylation patterns distinguish cluster of samples with higher recurrence rate (hazard ratio for recurrence = 0.48, 95% CI: 0.05&#x02013;0.92; log-rank test, p-value &#x0003c; 0.03). We also identified several clusters of correlated interchangeable methylation sites that can be used for the elaboration of biological interpretation of the resulting models and for further selection of the sites most suitable for designing diagnostic panels. LogLoss-BERAF is implemented as a standalone python code and open-source code is freely available from <ext-link ext-link-type="uri" xlink:href="https://github.com/bioinformatics-IBCH/logloss-beraf">https://github.com/bioinformatics-IBCH/logloss-beraf</ext-link> along with the models described in this article.</p></abstract><funding-group><award-group id="award001"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100003443</institution-id><institution>Ministry of Education and Science of the Russian Federation</institution></institution-wrap></funding-source><award-id>14.607.21.0068, Sep 23, 2014, unique ID RFMEFI60714X0068</award-id></award-group><funding-statement>This work was supported by the Russian Science Foundation project no. 14-50-00131 (for the machine learning and final framework), by the Ministry of Education and Science of Russian Federation no. 14.607.21.0068, unique ID RFMEFI60714&#x000d7;0068 (for the FRCC PCM dataset formation (GSE74013)), by the Russian Foundation for Basic Research projects no. 17-29-06076\17 (for the final model sites analysis) and no. 17-29-06063 (for the comparison with previously published models). There was no additional external funding received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="4"/><table-count count="4"/><page-count count="19"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All files are available from the Gene Expression Omnibus (GEO; <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/gds">https://www.ncbi.nlm.nih.gov/gds</ext-link>) (accession numbers GSE74013, GSE55479, GSE38240, GSE73549, GSE42752, GSE87571) and The Cancer Genome Atlas <ext-link ext-link-type="uri" xlink:href="https://portal.gdc.cancer.gov">https://portal.gdc.cancer.gov</ext-link>.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All files are available from the Gene Expression Omnibus (GEO; <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/gds">https://www.ncbi.nlm.nih.gov/gds</ext-link>) (accession numbers GSE74013, GSE55479, GSE38240, GSE73549, GSE42752, GSE87571) and The Cancer Genome Atlas <ext-link ext-link-type="uri" xlink:href="https://portal.gdc.cancer.gov">https://portal.gdc.cancer.gov</ext-link>.</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>Prostate cancer (PC) is one of the most frequently diagnosed oncological diseases in males worldwide [<xref rid="pone.0204371.ref001" ref-type="bibr">1</xref>]. Like most other cancers, the early stages of PC are characterized by an asymptomatic course, which substantially impedes its early diagnosis [<xref rid="pone.0204371.ref002" ref-type="bibr">2</xref>]. Advances in the past decade of research, particularly in genetic studies, have provided a deeper understanding of the molecular mechanisms underlying PC pathogenesis, and these advances can serve as the basis for the development of effective molecular genetic methods for early diagnosis of this disease [<xref rid="pone.0204371.ref003" ref-type="bibr">3</xref>].</p><p>The latest experimental data have clarified the role of genetic and epigenetic factors in PC pathogenesis [<xref rid="pone.0204371.ref004" ref-type="bibr">4</xref>]. Among these factors, epigenetic alterations, particularly aberrant DNA methylation of CpG dinucleotides in genes, are of special interest. These alterations are often functionally related to the expression regulation of tumor suppressors and oncogenes at early stages of both prostate cancer and other types of oncological diseases [<xref rid="pone.0204371.ref005" ref-type="bibr">5</xref>,<xref rid="pone.0204371.ref006" ref-type="bibr">6</xref>].</p><p>Despite the advantages of this approach, the application of such epigenetic markers in diagnostic practice tends to have certain limitations, mostly at the technical level. Among the most widely used are whole-genome DNA methylation analyses based on either high-throughput sequencing or DNA hybridization arrays. For example, the Infinium HumanMethylation450 BeadChip array (HM450) can be used to estimate methylation levels for 98,9% of all characterized genes (according to the UCSC RefGenes database) [<xref rid="pone.0204371.ref007" ref-type="bibr">7</xref>]. However, such methods are not always suitable for routine laboratory diagnostics due to their high cost and complexity compared to PCR-based methods and due to the large amount of sample DNA required for the analysis. Quantitative methylation-specific PCR techniques, such as methylation-sensitive high-resolution melting (MS-HRM), which requires only 10 ng of DNA, are more convenient for clinical pathology analysis, and their development may allow clinicians to switch to less invasive diagnostic methods in the future [<xref rid="pone.0204371.ref008" ref-type="bibr">8</xref>]. However, despite their relative technological simplicity, these methods are not designed to analyze large numbers of markers simultaneously. Thus, the number of candidate CpG sites often must be restricted, which results in decreased sensitivity and specificity of the test.</p><p>High molecular heterogeneity of tumors compared to non-tumor tissues, which includes DNA methylation patterns, presents another challenge for clinical diagnostics. Significant DNA methylation variability in tumors is common in prostate cancer and has been shown to be the case for many other oncological diseases [<xref rid="pone.0204371.ref009" ref-type="bibr">9</xref>]. The existence of different molecular tumor subtypes makes it difficult, and sometimes even impossible, to select informative and reproducible diagnostic signatures, and this is the reason why the results of conventional classification methods for marker selection from limited datasets are often irreproducible with independent data [<xref rid="pone.0204371.ref010" ref-type="bibr">10</xref>]. The simplest method of forming a marker panel is the selection of top N differentially methylated sites. The major problem of this approach is the possibility of redundant markers being included in the model due to the fact that the selection of each next marker is independent of the markers already present in the model. Moreover, this method does not allow to identify markers that are specific only for a small cluster of samples belonging to a certain heterogeneity subgroup because such markers have insufficient level of differential methylation. Many experimental studies suggest that methylation site selection methods, including both the estimation of the average difference in methylation levels and calculation of the differential methylation variability of different sites, may prove to be more reliable [<xref rid="pone.0204371.ref011" ref-type="bibr">11</xref>]. Thus, there is a need for an approach that would take into account the high variability of the source dataset of analyzed candidate markers and produce a limited number of final markers.</p><p>Currently used feature selection methods can be divided into three main categories [<xref rid="pone.0204371.ref012" ref-type="bibr">12</xref>]: embed, wrapper, and filtering methods. Embed methods are characterized by joint optimization of the classifier, model construction and feature subset selection. The main approach here is regularization, which is implemented in well-known and widely used algorithms such as LASSO [<xref rid="pone.0204371.ref013" ref-type="bibr">13</xref>]. Wrapper methods include initial training on different factor subsets, and the final model is defined by optimization of a previously selected metric. These methods use forward selection (the algorithm starts from an empty set, and new factors are iteratively added to it) and backwards selection (the algorithm iteratively removes &#x0201c;odd&#x0201d; factors from the set) [<xref rid="pone.0204371.ref012" ref-type="bibr">12</xref>]. This method reconstructs interactions between factors more effectively but at the same time risks overfitting when a dataset contains few samples and many factors. Finally, filtering methods are based on statistical tests and usually process factors separately to calculate their correlation with the goal variable. These methods tend to be faster than others, but they do not consider interactions between factors.</p><p>Many studies [<xref rid="pone.0204371.ref014" ref-type="bibr">14</xref>&#x02013;<xref rid="pone.0204371.ref022" ref-type="bibr">22</xref>] have focused on feature selection analyses for gene expression and mutational data, but there are few studies describing similar approaches to methylation data. Alkuhlani et al. suggested using a combination of feature selection through Fisher&#x02019;s test and t-tests, a genetic algorithm with SVM-RFE as an optimizable function, and an SVM classifier [<xref rid="pone.0204371.ref023" ref-type="bibr">23</xref>]. Ma Z et al. used a variational Bayes beta mixture model as a method for selection and optimization of prognostic markers [<xref rid="pone.0204371.ref024" ref-type="bibr">24</xref>]. However, neither of these models supports initial restriction of the factor subset size, which makes the resulting sets hard to translate into routine laboratory practice.</p><p>The aim of this study was to develop a framework for selection of a limited number of diagnostically informative DNA methylation sites and to estimate its potential diagnostic efficiency. We evaluated the method using publicly available whole-genome DNA methylation data for prostate cancer, as one of the highly heterogeneous cancers, and for several other oncological diseases.</p></sec><sec sec-type="materials|methods" id="sec002"><title>Materials and methods</title><sec id="sec003"><title>Datasets</title><p>DNA methylation data used in this study were acquired using lllumina Infinium HumanMethylation 450k BeadChip technology [<xref rid="pone.0204371.ref025" ref-type="bibr">25</xref>]. The development of the model and the estimation of its parameters were performed with the use of DNA methylation data from the TCGA PRAD project. We used DNA methylation data from tumor and corresponding non-tumor (morphologically unchanged) prostate tissue samples. We applied the framework to other types of oncological diseases to demonstrate its efficiency. Since one of the promising current trends is non-invasive PC diagnostics based on DNA methylation markers obtained from urine samples [<xref rid="pone.0204371.ref026" ref-type="bibr">26</xref>,<xref rid="pone.0204371.ref027" ref-type="bibr">27</xref>], we also analyzed methylation data for urothelial bladder carcinoma (BLCA), kidney renal clear cell carcinoma (KIRC), and kidney renal papillary cell carcinoma (KIRP). As PC is often co-localized with colon adenocarcinoma, we also applied the framework to TCGA COAD data. The samples used for the framework development and validation are listed in <xref rid="pone.0204371.t001" ref-type="table">Table 1</xref>.</p><table-wrap id="pone.0204371.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0204371.t001</object-id><label>Table 1</label><caption><title>List of tumor (T) and non-tumor (N) samples and datasets used for model training and validation.</title></caption><alternatives><graphic id="pone.0204371.t001g" xlink:href="pone.0204371.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Source</th><th align="left" rowspan="1" colspan="1">Training Set</th><th align="left" rowspan="1" colspan="1">Test Set</th><th align="left" rowspan="1" colspan="1">Total</th></tr></thead><tbody><tr><td align="center" colspan="4" rowspan="1"><bold>Prostate cancer</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>FRCC PCM FMBA</bold></td><td align="left" rowspan="1" colspan="1">8T, 11N</td><td align="left" rowspan="1" colspan="1">13T, 16N</td><td align="left" rowspan="1" colspan="1">48</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>TCGA (PRAD)</bold></td><td align="left" rowspan="1" colspan="1">117T, 15N</td><td align="left" rowspan="1" colspan="1">176T, 23N</td><td align="left" rowspan="1" colspan="1">331</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>GSE55479</bold></td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">143T, 0N</td><td align="left" rowspan="1" colspan="1">143</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>GSE38240</bold></td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">8T, 4N</td><td align="left" rowspan="1" colspan="1">12</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>GSE73549</bold></td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">77T, 15N</td><td align="left" rowspan="1" colspan="1">92</td></tr><tr><td align="center" colspan="4" rowspan="1"><bold>Bladder cancer</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>TCGA (BLCA)</bold></td><td align="left" rowspan="1" colspan="1">134T, 9N</td><td align="left" rowspan="1" colspan="1">201T, 14N</td><td align="left" rowspan="1" colspan="1">490</td></tr><tr><td align="center" colspan="4" rowspan="1"><bold>Colorectal cancer</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>TCGA (COAD)</bold></td><td align="left" rowspan="1" colspan="1">133T, 15N</td><td align="left" rowspan="1" colspan="1">200T, 22N</td><td align="left" rowspan="1" colspan="1">370</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>FRCC PCM FMBA</bold></td><td align="left" rowspan="1" colspan="1">6T, 9N</td><td align="left" rowspan="1" colspan="1">8T, 11N</td><td align="left" rowspan="1" colspan="1">34</td></tr><tr><td align="center" colspan="4" rowspan="1"><bold>Kidney cancer (KIRC)</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>TCGA (KIRC)</bold></td><td align="left" rowspan="1" colspan="1">116T, 52N</td><td align="left" rowspan="1" colspan="1">174T, 78N</td><td align="left" rowspan="1" colspan="1">420</td></tr><tr><td align="center" colspan="4" rowspan="1"><bold>Kidney cancer (KIRP)</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>TCGA (KIRP)</bold></td><td align="left" rowspan="1" colspan="1">101T, 63N</td><td align="left" rowspan="1" colspan="1">151T, 104N</td><td align="left" rowspan="1" colspan="1">419</td></tr></tbody></table></alternatives></table-wrap><sec id="sec004"><title>Prostate adenocarcinoma</title><p>FRCC PCM dataset: our own dataset for 48 samples (GSE74013) is available at Gene Expression Omnibus (GEO; <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nig.gov/geo/">www.ncbi.nlm.nig.gov/geo/</ext-link>); TCGA PRAD dataset: data for 331 samples obtained from The Cancer Genome Atlas (<ext-link ext-link-type="uri" xlink:href="https://tcga-data.nci.nih.gov/tcga/">https://tcga-data.nci.nih.gov/tcga/</ext-link>, TCGA PRAD). The samples were selected according to age and clinical criteria (a detailed description is provided in <xref ref-type="supplementary-material" rid="pone.0204371.s002">S1 Table</xref>); PRAD datasets downloaded from Gene Expression Omnibus: GSE55479 (143 samples), GSE38240 (12 samples) and GSE73549 (92 samples).</p></sec><sec id="sec005"><title>Urothelial bladder carcinoma</title><p>TCGA BLCA dataset: 351 samples.</p></sec><sec id="sec006"><title>Kidney cancer</title><p>Renal clear cell carcinoma&#x02013;TCGA KIRC dataset: 420 samples; Kidney renal papillary cell carcinoma&#x02013;TCGA-KIRP dataset: 419 samples.</p></sec><sec id="sec007"><title>Colon adenocarcinoma</title><p>FRCC PCM dataset: our own data for 34 samples (GSE42752); TCGA COAD dataset: 370 samples.</p></sec><sec id="sec008"><title>White blood cells</title><p>For additional validation of the model, we used DNA methylation data from 200 leukocyte blood fraction samples obtained from individuals of different ages (GSE87571).</p></sec></sec><sec id="sec009"><title>Preprocessing</title><p>Preprocessing of raw IDAT files was performed with the RnBeads package [<xref rid="pone.0204371.ref028" ref-type="bibr">28</xref>]. Systematic batch effect correction was done using the ComBat algorithm from the sva package [<xref rid="pone.0204371.ref029" ref-type="bibr">29</xref>]. Normalization and background correction were performed with NOOB [<xref rid="pone.0204371.ref030" ref-type="bibr">30</xref>] and BMIQ [<xref rid="pone.0204371.ref031" ref-type="bibr">31</xref>] algorithms, which demonstrated the best results corrected for technical errors when used in combination [<xref rid="pone.0204371.ref032" ref-type="bibr">32</xref>].</p></sec><sec id="sec010"><title>Combined feature selection</title><p>The methylation level of each CpG site is represented as a beta-value, &#x003b2;, which is calculated as follows [<xref rid="pone.0204371.ref025" ref-type="bibr">25</xref>]:
<disp-formula id="pone.0204371.e001"><alternatives><graphic xlink:href="pone.0204371.e001.jpg" id="pone.0204371.e001g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M1"><mml:mi mathvariant="normal">&#x003b2;</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">M</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">M</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">U</mml:mi><mml:mo>+</mml:mo><mml:mn>100</mml:mn></mml:mrow></mml:mfrac></mml:math></alternatives><label>(1)</label></disp-formula>
where M is the methylated intensity and U is the unmethylated intensity of each probe.</p><p>Henceforth, we will refer to a vector of beta values &#x003b2; &#x02208; (0, 1)<sup>N</sup>, where N is the number of samples, as a feature. Further feature selection is based on the following biological and technically required rules and limitations:</p><p>A selected feature set (henceforth called a signature) can include heterogeneously methylated CpG sites.</p><p>A selected signature must include not more than a predefined number of CpG sites (factors).</p><p>Methylation values of CpG sites included in the signature must differ between the analyzed classes (i.e., pathology vs. non-pathology) by more than a predefined value and may vary within the experimental level of accuracy.</p><p>The feature selection method must be applicable to unbalanced sets, where the number of the samples from one class (i.e., pathology) is much greater than that of another or where the number of factors is much greater than the total number of samples.</p><p>The scheme of the model construction algorithm is shown in <xref ref-type="fig" rid="pone.0204371.g001">Fig 1</xref>. Let P be the upper limit for the number of features in the diagnostic panel, C&#x02014;number of analyzed classes, &#x00394;&#x003b2;&#x02014;minimum difference between average methylation levels. The first step consists of the selection of the factors for which the average methylation between at least one pair of groups differs by more than the user-defined value &#x00394;&#x003b2; (<xref ref-type="disp-formula" rid="pone.0204371.e002">Eq 2</xref>):
<disp-formula id="pone.0204371.e002"><alternatives><graphic xlink:href="pone.0204371.e002.jpg" id="pone.0204371.e002g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M2"><mml:mo>&#x02203;</mml:mo><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">i</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="normal">j</mml:mi><mml:mo>&#x02208;</mml:mo><mml:mo>{</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mo>&#x02026;</mml:mo><mml:mo>,</mml:mo><mml:mi mathvariant="normal">C</mml:mi></mml:mrow><mml:mo>}</mml:mo><mml:mo>:</mml:mo><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:msubsup><mml:mrow><mml:mi mathvariant="normal">&#x003b2;</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">n</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mo stretchy="false">)</mml:mo><mml:mo>&#x02212;</mml:mo><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:msubsup><mml:mrow><mml:mi mathvariant="normal">&#x003b2;</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">j</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">m</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mo stretchy="false">)</mml:mo><mml:mo>)</mml:mo></mml:mrow><mml:mo>&#x0003e;</mml:mo><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mi mathvariant="normal">&#x003b2;</mml:mi></mml:math></alternatives><label>(2)</label></disp-formula>
where <inline-formula id="pone.0204371.e003"><alternatives><graphic xlink:href="pone.0204371.e003.jpg" id="pone.0204371.e003g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M3"><mml:msubsup><mml:mrow><mml:mi mathvariant="normal">&#x003b2;</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">k</mml:mi></mml:mrow></mml:msubsup></mml:math></alternatives></inline-formula> represent methylation beta values in a sample subset k belonging to class i.</p><fig id="pone.0204371.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0204371.g001</object-id><label>Fig 1</label><caption><title>Pipeline of the proposed method.</title></caption><graphic xlink:href="pone.0204371.g001"/></fig><p>The next step involves a combination of two feature selection methods. The first one is randomized logistic regression (RLR), also known as the stability method [<xref rid="pone.0204371.ref033" ref-type="bibr">33</xref>], implemented in the scikit-learn 0.17.1 package [<xref rid="pone.0204371.ref034" ref-type="bibr">34</xref>]. In RLR, the original set is split randomly, and the sites that have non-zero coefficients after regularization are selected from the resulting subsets. The RLR method was selected because it allows selection of a limited number of the most significant sites for classification using L1 regularization and because it can identify highly correlated sites and include them into the resulting set due to random splitting at each iteration of randomization. Additionally, site selection on a subset of samples can potentially account for heterogeneity among samples. Nevertheless, because of the stochasticity of the process, not all highly correlated features may be included in the resulting set, as some of them may be discarded during model construction as non-informative compared to those already included in the model. However, these features can be as valuable as the selected ones; thus, we perform a pairwise correlational analysis in order to avoid data loss.</p><p>In the following steps, we used a random forest (RF) algorithm. RF is a popular and efficient method for classification problems and is based on ensembles of decision trees and bootstrap aggregating, which is designed to avoid overfitting [<xref rid="pone.0204371.ref035" ref-type="bibr">35</xref>]. To handle unbalanced data, sample weights are adjusted inversely proportional to class frequencies.</p><p>A trained classifier provides the estimate of the importance factor used for sample classification, which can be used for further feature selection.</p><p>The feature importance threshold is then varied to construct a random forest for each factor subset, and 10-fold cross-validation is performed. This approach is a popular machine learning method that provides an unbiased estimate of model accuracy [<xref rid="pone.0204371.ref036" ref-type="bibr">36</xref>]. Classification efficiency is estimated based on several metrics: precision, recall and LogLoss, also called cross-entropy loss or logistic regression loss [<xref rid="pone.0204371.ref037" ref-type="bibr">37</xref>]. The latter represents a classifier accuracy estimate and allows the prediction of classes themselves (y<sub>ij</sub>) and their probabilities (p<sub>ij</sub>). (<xref ref-type="disp-formula" rid="pone.0204371.e004">Eq 3</xref>)
<disp-formula id="pone.0204371.e004"><alternatives><graphic xlink:href="pone.0204371.e004.jpg" id="pone.0204371.e004g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M4"><mml:mi>L</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi><mml:mi>L</mml:mi><mml:mi>o</mml:mi><mml:mi>s</mml:mi><mml:mi>s</mml:mi><mml:mo>=</mml:mo><mml:mo>&#x02212;</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>N</mml:mi></mml:mrow></mml:mfrac><mml:mrow><mml:mstyle displaystyle="false"><mml:msubsup><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>N</mml:mi></mml:mrow></mml:msubsup></mml:mstyle><mml:mrow><mml:mrow><mml:mstyle displaystyle="false"><mml:msubsup><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msubsup></mml:mstyle><mml:mrow><mml:msub><mml:mrow><mml:mi>y</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>*</mml:mo><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:math></alternatives><label>(3)</label></disp-formula></p><p>The usage of LogLoss metrics is motivated by the fact that we want to impose penalties both for false predictions and for low confidence in true ones. This approach allows us to identify less noisy sites.</p><p>Next, when model quality values for different feature subsets have been obtained, a local minimum search for the LogLoss function of the number of factors is performed in the neighborhood of the desired number of sites. The resulting set of factors is selected as a set of minimum size such that its logistic regression loss value differs from that of the local minimum by not more than one standard error. (<xref ref-type="disp-formula" rid="pone.0204371.e005">Eq 4</xref>)
<disp-formula id="pone.0204371.e005"><alternatives><graphic xlink:href="pone.0204371.e005.jpg" id="pone.0204371.e005g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M5"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">min</mml:mi></mml:mrow><mml:mrow><mml:mi>x</mml:mi><mml:mo>&#x02208;</mml:mo><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>P</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>x</mml:mi></mml:mrow></mml:mrow><mml:mo>:</mml:mo><mml:mo>|</mml:mo><mml:mrow><mml:mi>L</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi><mml:mi>L</mml:mi><mml:mi>o</mml:mi><mml:mi>s</mml:mi><mml:mi>s</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mo stretchy="false">)</mml:mo><mml:mo>&#x02212;</mml:mo><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">min</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mo>&#x02208;</mml:mo><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>P</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msub></mml:mrow><mml:mspace width="0.25em"/><mml:mrow><mml:mi>L</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi><mml:mi>L</mml:mi><mml:mi>o</mml:mi><mml:mi>s</mml:mi><mml:mi>s</mml:mi><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mrow><mml:mo>|</mml:mo><mml:mo>&#x0003c;</mml:mo><mml:mn>1</mml:mn><mml:mspace width="0.25em"/><mml:mi>s</mml:mi><mml:mo>.</mml:mo><mml:mi>e</mml:mi><mml:mo>.</mml:mo></mml:math></alternatives><label>(4)</label></disp-formula></p><p>One of the advantages of LogLoss usage is the ability to detect outliers. For example, if some samples in the input data are assigned to a wrong class or differ substantially from others, the resulting model will be strongly penalized for their use, and the loss function value itself will be relatively high. Class membership predictions and input object class data are incorporated to construct a list of potential outliers by marking objects for which the probability of belonging to a wrong class is above the threshold.</p><p>The resulting classification performance was evaluated using AUC metrics.</p></sec></sec><sec id="sec011"><title>Results and discussion</title><p>The developed framework was applied to the datasets listed in <xref rid="pone.0204371.t001" ref-type="table">Table 1</xref> with the following parameters: user-defined minimum variation of the average methylation levels between classes &#x00394;&#x003b2; &#x02265; 0.2; 1500 RLR iterations, a random forest of 500 trees for factor importance estimation, and an intermediate random forest consisting of 1000 trees parameters were obtained through nested cross-validation.</p><sec id="sec012"><title>Model construction for prostate cancer</title><p>To construct a diagnostic model for prostate adenocarcinoma, we analyzed 626 samples: the training set contained 151 samples, and the independent test set contained 475 samples. The resulting model produced by LogLoss-BERAF included data from 9 methylation sites (<xref rid="pone.0204371.t002" ref-type="table">Table 2</xref>, <xref ref-type="supplementary-material" rid="pone.0204371.s003">S2 Table</xref>) that showed high levels of differential methylation between the groups (<xref ref-type="supplementary-material" rid="pone.0204371.s001">S1 Fig</xref>); the model demonstrated 0.95 recall, 0.95 precision, a 0.95 F1-score and 0.97 AUC (95% CI: 0.94&#x02013;0.99) on the test set.</p><table-wrap id="pone.0204371.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0204371.t002</object-id><label>Table 2</label><caption><title>Prostate adenocarcinoma classification model sites with their positions and their corresponding gene name and group.</title></caption><alternatives><graphic id="pone.0204371.t002g" xlink:href="pone.0204371.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="justify" rowspan="1" colspan="1">IlmnID</th><th align="justify" rowspan="1" colspan="1">Chr</th><th align="justify" rowspan="1" colspan="1">Position</th><th align="justify" rowspan="1" colspan="1">Gene name</th><th align="justify" rowspan="1" colspan="1">Group</th></tr><tr><th align="center" colspan="5" rowspan="1">Prostate adenocarcinoma</th></tr></thead><tbody><tr><td align="justify" rowspan="1" colspan="1">cg02361803</td><td align="justify" rowspan="1" colspan="1">chr1</td><td align="justify" rowspan="1" colspan="1">2014371</td><td align="justify" rowspan="1" colspan="1">PRKCZ</td><td align="justify" rowspan="1" colspan="1">Body</td></tr><tr><td align="justify" rowspan="1" colspan="1">cg11448068</td><td align="justify" rowspan="1" colspan="1">chr2</td><td align="justify" rowspan="1" colspan="1">191045026</td><td align="justify" rowspan="1" colspan="1">C2orf88</td><td align="justify" rowspan="1" colspan="1">TSS1500</td></tr><tr><td align="justify" rowspan="1" colspan="1">cg16100120</td><td align="justify" rowspan="1" colspan="1">chr2</td><td align="justify" rowspan="1" colspan="1">56150475</td><td align="justify" rowspan="1" colspan="1">EFEMP1</td><td align="justify" rowspan="1" colspan="1">TSS200</td></tr><tr><td align="justify" rowspan="1" colspan="1">cg00817367</td><td align="justify" rowspan="1" colspan="1">chr12</td><td align="justify" rowspan="1" colspan="1">52401214</td><td align="justify" rowspan="1" colspan="1">GRASP</td><td align="justify" rowspan="1" colspan="1">Body</td></tr><tr><td align="justify" rowspan="1" colspan="1">cg18844382</td><td align="justify" rowspan="1" colspan="1">chr14</td><td align="justify" rowspan="1" colspan="1">23834977</td><td align="justify" rowspan="1" colspan="1">EFS</td><td align="justify" rowspan="1" colspan="1">TSS200</td></tr><tr><td align="justify" rowspan="1" colspan="1">cg00402172</td><td align="justify" rowspan="1" colspan="1">chr16</td><td align="justify" rowspan="1" colspan="1">68118754</td><td align="justify" rowspan="1" colspan="1">NFATC3</td><td align="justify" rowspan="1" colspan="1">TSS1500</td></tr><tr><td align="justify" rowspan="1" colspan="1">cg14621217</td><td align="justify" rowspan="1" colspan="1">chr17</td><td align="justify" rowspan="1" colspan="1">80944134</td><td align="justify" rowspan="1" colspan="1">B3GNTL1</td><td align="justify" rowspan="1" colspan="1">Body</td></tr><tr><td align="justify" rowspan="1" colspan="1">cg16849024</td><td align="justify" rowspan="1" colspan="1">chr19</td><td align="justify" rowspan="1" colspan="1">41934210</td><td align="justify" rowspan="1" colspan="1">B3GNT8</td><td align="justify" rowspan="1" colspan="1">5'UTR</td></tr><tr><td align="justify" rowspan="1" colspan="1">cg22059073</td><td align="justify" rowspan="1" colspan="1">chr22</td><td align="justify" rowspan="1" colspan="1">17602570</td><td align="justify" rowspan="1" colspan="1">CECR6</td><td align="justify" rowspan="1" colspan="1">TSS1500</td></tr></tbody></table></alternatives></table-wrap></sec><sec id="sec013"><title>Algorithm allows to construct high efficiency panels of biomarkers without a priori knowledge of their diagnostic efficacy</title><p>Prostate cancer analysis provides a good opportunity for the optimization of marker selection methods because epigenetic alterations are highly prevalent and arise early in prostate tumorigenesis. The most recent studies have identified many DNA methylation alterations as potential biomarkers for prostate cancer diagnostics. Feature selection was generally carried out based on a prioritized list of genes showing the most significant differences in methylation levels between tumor and non-tumor sample groups.</p><p><italic>GSTP1</italic> is the most well-characterized epigenetic biomarker for PC. DNA methylation of <italic>GSTP1</italic> is present in almost all PC cells but is absent or present in low levels in normal cells. However, the estimation of <italic>GSTP1</italic> methylation levels does not demonstrate high specificity and recall (0.88 and 0.91 respectively) of <italic>GSTP1</italic> as a diagnostic biomarker [<xref rid="pone.0204371.ref038" ref-type="bibr">38</xref>&#x02013;<xref rid="pone.0204371.ref040" ref-type="bibr">40</xref>]. This issue could be addressed in part using multigene promoter methylation testing. For the moment, good clinical utility method of estimating methylation levels has been shown for promoters of <italic>GSTP1</italic>, <italic>APC</italic> and <italic>RASSF1</italic> genes [<xref rid="pone.0204371.ref041" ref-type="bibr">41</xref>]. This model may be used to predict negative histopathological results in repeat prostate biopsies.</p><p>To assess the diagnostic performance of the developed model, we compared its results to the precision and recall values calculated for the 3-gene model described by Stewart et al. (2013) and several other published multigene models. We reproduced the calculations of these models and applied them to the datasets being analyzed in this study. The 3-gene model based on combined analysis of average methylation levels for <italic>GSTP1</italic>, <italic>RASSF1</italic> and <italic>APC</italic> demonstrated good results when applied to our data: 0.92 AUC (95% CI: 0.87&#x02013;0.96), 0.91 precision, 0.89 recall, and 0.89 F1-score, which nonetheless represents a lower performance compared to our model.</p><p>Chung et al. demonstrated the diagnostic significance of <italic>SPOCK2</italic> and <italic>NSE1</italic> gene methylation with 0.80 recall and 0.95 precision (AUC was not reported) [<xref rid="pone.0204371.ref042" ref-type="bibr">42</xref>]. The proposed logistic regression model applied to our data had 0.90 precision, 0.87 recall and an 0.88 F1-score with 0.91 AUC (95% CI: 0.86&#x02013;0.96).</p><p>One of the most common approaches is to first calculate differential methylation for individual sites and then select statistically significant differences to construct a model. We applied this method to select 3 methylation sites (<italic>cg00054525</italic>, <italic>cg16794576</italic> and <italic>cg24581650</italic>) using a linear mixed model [<xref rid="pone.0204371.ref043" ref-type="bibr">43</xref>] and then used logistic regression to construct a diagnostic model that had 0.845 recall and 0.917 specificity, with the resulting AUC of 0.92 for the test set. When trained and tested on our datasets, the model demonstrated 0.93 AUC (95% CI: 0.88&#x02013;0.95), 0.92 precision, 0.92 recall, and a 0.91 F1-score.</p><p>Tumor-associated events at the DNA methylation level can vary greatly in scale in prostate cancer, and therefore, it is reasonable to consider a signature that uses more than 3 factors; their selection can be conducted independently without an initial rating of all sites and extraction of a top subset. For example, Tang et al. [<xref rid="pone.0204371.ref044" ref-type="bibr">44</xref>] considered 8 hypermethylated sites (<italic>cg06363129</italic>, <italic>cg08843517</italic>, <italic>cg03576469</italic>, <italic>cg05385513</italic>, <italic>cg07220448</italic>, <italic>cg11417025</italic>, <italic>cg20883831</italic> and <italic>cg23824801</italic>) located in promoter regions. The models constructed using logistic regression had from 0.91 to 0.94 AUC for individual methylation sites and 0.94 AUC when a combination of sites was used (recall and precision values were not reported). The 8-site model reproduced on our datasets demonstrated 0.95 AUC (95% CI: 0.90&#x02013;0.98), 0.93 recall, 0.92 precision, and a 0.93 F1-score. All obtained values are listed in <xref ref-type="supplementary-material" rid="pone.0204371.s004">S3 Table</xref>.</p><p>Thus, ensemble methods for model construction demonstrate higher efficiency than the identification of individual sites due to their capability to reveal various connections between factors and predicted classes, which provides more stable and reproducible results. Additionally, in contrast to supervised approaches to marker selection that impose tight restrictions on the candidate sites in terms of their methylation levels, variability, and differences between the groups or gene information, our unsupervised method has demonstrated high classification performance, both absolute and in comparison, with other prostate cancer diagnostic panels. This framework has also allowed us to build a small-sized signature and expand the list of known potential prostate cancer biomarkers.</p></sec><sec id="sec014"><title>Highly correlated model sites can be interchanged without a loss of diagnostic significance</title><p>Highly variable data, such as DNA methylation profiles in oncological diseases, are often characterized by the presence of several factor subsets that show equal or close classification efficacy [<xref rid="pone.0204371.ref045" ref-type="bibr">45</xref>,<xref rid="pone.0204371.ref046" ref-type="bibr">46</xref>]. In our model, many highly correlated sites can be dismissed at the construction step because they do not carry new information compared to those already included in the model. However, such correlated sites can be as informative as individual sites from the model (<xref ref-type="supplementary-material" rid="pone.0204371.s005">S4 Table</xref>). We aimed to assess how replacing the sites from the resulting model with highly correlated sites could affect the classification efficacy. Sites were considered highly correlated if their Pearson correlation coefficient was greater than 0.85.</p><p>We performed 10,000 permutations where each site from the model could be replaced by one of the correlated sites. The resulting classification efficacy had an AUC value of 0.93 (95% CI: 0.90&#x02013;0.97). Thus, certain model sites could be substituted with ones more convenient for practical use, i.e., considering region mappability or applicability for primer design.</p></sec><sec id="sec015"><title>Method for model construction showed relatively high stability</title><p>In addition to accuracy, another important characteristic of an algorithm is its stability, which is crucial for tasks involving few samples and high dimensionality. Algorithm stability is defined as the variability of factor selection resulting from minor changes in the training set. For k sub-samplings from the initial set, the final stability is estimated as the average agreement over all subsampling pairs. Let <italic>f</italic><sub><italic>i</italic></sub> be the i-th subsampling, then the agreement can be calculated as Kuncheva index [<xref rid="pone.0204371.ref047" ref-type="bibr">47</xref>]
<disp-formula id="pone.0204371.e006"><alternatives><graphic xlink:href="pone.0204371.e006.jpg" id="pone.0204371.e006g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M6"><mml:mi>S</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>2</mml:mn><mml:mrow><mml:mstyle displaystyle="false"><mml:msubsup><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msubsup></mml:mstyle><mml:mrow><mml:mrow><mml:mstyle displaystyle="false"><mml:msubsup><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msubsup></mml:mstyle><mml:mrow><mml:mfrac><mml:mrow><mml:mi>r</mml:mi><mml:mi>N</mml:mi><mml:mo>&#x02212;</mml:mo><mml:msup><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mi>s</mml:mi><mml:mo>(</mml:mo><mml:mrow><mml:mi>N</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>s</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mo>(</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mfrac></mml:math></alternatives><label>(5)</label></disp-formula>
where N is the initial number of factors, r = |<italic>f</italic><sub><italic>i</italic></sub>&#x022c2;<italic>f</italic><sub><italic>j</italic></sub>| is the number of identical elements in the subsamplings, s = |<italic>f</italic><sub><italic>i</italic></sub>| = |<italic>f</italic><sub><italic>j</italic></sub>|.</p><p>Due to the identified characteristics of correlated sites, factors combined with correlated ones were used as <italic>f</italic><sub><italic>i</italic></sub>. Our experiment included 100 bootstrapping iterations with 90% of samples randomly selected at each iteration and resulted in a relatively high Kuncheva index of 0.72, while LASSO alone obtained score of 0.55.</p></sec><sec id="sec016"><title>The developed framework allows methylation sites that are highly heterogeneous between groups to be included in the resulting model</title><p>The key point of the algorithm is its capability of efficient sample classification regarding the differential variability of the sites used in the model. In contrast, with supervised approaches based on strict selection of candidate markers by differential methylation level, our method allows for certain intra-group methylation level variability of candidate markers by differential methylation level, our method allows for certain intra-group methylation level variability of individual sites. For example, the methylation pattern of resulting model CpG sites in cancer samples allows them to be split into at least three main clusters (<xref ref-type="fig" rid="pone.0204371.g002">Fig 2A</xref>) using a k-means algorithm (skilearn v. 0.17.1). Different methylation patterns of samples combined with predictive values of the sites can be used for biological interpretation of metagenetic manifestation of the disease heterogeneity. Nonetheless, the clustering results produced by our model do not identify the same subtypes as those obtained by methylation analysis of the TCGA prostate cancer dataset and reported in The Cancer Genome Atlas Research Network study [<xref rid="pone.0204371.ref048" ref-type="bibr">48</xref>].</p><fig id="pone.0204371.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0204371.g002</object-id><label>Fig 2</label><caption><p><bold>A.</bold> Clustering of tumor samples by shared methylation patterns of the sites included in the prostate cancer classification model. The X axis shows indices of model sites (0: cg02361803; 1: cg16100120; 2: cg11448068; 3: cg00817367; 4: cg18844382; 5: cg00402172; 6: cg14621217; 7: cg16849024; and 8: cg22059073). <bold>B.</bold> AUC changes depending on the noise level, delta, introduced into methylation levels of the sites included in the prostate cancer classification model. <bold>C.</bold> PCA graph for the sites of the PRAD diagnostic model with methylation groups assigned according to the data for leukocyte blood fraction from nominally healthy people.</p></caption><graphic xlink:href="pone.0204371.g002"/></fig><p>Nevertheless, the survival analysis of disease recurrence for samples from different clusters demonstrated statistically significant difference between clusters 2 and 3 (hazard ratio for recurrence = 0.48, 95% CI: 0.05&#x02013;0.92; log-rank test, p-value &#x0003c; 0.03) (<xref ref-type="fig" rid="pone.0204371.g003">Fig 3</xref>), which indicates additional potential clinical applicability.</p><fig id="pone.0204371.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0204371.g003</object-id><label>Fig 3</label><caption><title>Kaplan-Meier curves for samples from second and third clusters.</title><p>Clusters introduced in <xref ref-type="fig" rid="pone.0204371.g002">Fig 2A</xref>.</p></caption><graphic xlink:href="pone.0204371.g003"/></fig></sec><sec id="sec017"><title>The proposed method demonstrates tolerance to input data errors</title><p>One of the problems that arise in practical application of a machine learning model is its tolerance to noise in the input data, which occurs because of a batch effect, technical errors and other errors [<xref rid="pone.0204371.ref049" ref-type="bibr">49</xref>]. To assess our model, we gradually introduced noise &#x00394;&#x003bc;<sub>i</sub> into the methylation levels of the input data. &#x00394;&#x003bc;<sub>i</sub> values were varied randomly in the range of (&#x02212;&#x00394;&#x003bc;<sub>i</sub>; +&#x00394;&#x003bc;<sub>i</sub>), the AUC was calculated for each &#x00394;&#x003bc;<sub>i</sub>, and then, &#x00394;&#x003bc;<sub>i</sub> was increased (<xref ref-type="fig" rid="pone.0204371.g002">Fig 2B</xref>). In total, 1000 iterations were performed to estimate AUC variance at each step. The model demonstrated robustness at noise levels approximately 0.16 of the methylation <italic>&#x003b2;</italic>-value, which represents a good performance and suggests an opportunity for further development of the model into a sufficiently fast, inexpensive, robust and widely available method that will be useful for routine clinical diagnostics [<xref rid="pone.0204371.ref050" ref-type="bibr">50</xref>,<xref rid="pone.0204371.ref051" ref-type="bibr">51</xref>].</p><p>This model has also produced high AUC values on sufficiently noisy data (&#x000b1;0.5 <italic>&#x003b2;</italic>-value). We assumed that this result was due to the prevalence of tumor samples in the dataset and the associated high dispersion of methylation values compared to non-tumor samples. To check this hypothesis, we tested the model for type I errors by applying it to leukocyte blood fraction methylation data from 200 samples obtained from nominally healthy people. The PCA graph is shown in <xref ref-type="fig" rid="pone.0204371.g002">Fig 2C</xref>. The model classified all samples as non-tumors, which confirms the hypothesis that due to the high intragroup heterogeneity of tumor samples, the model tends to classify samples with highly non-uniform methylation levels as tumors. This finding also demonstrates the effective performance of the model considering the considerable discrepancy between the sizes of the datasets being analyzed.</p></sec><sec id="sec018"><title>Biological function of genes containing model methylation sites and correlated sites</title><p>The present study is primarily concerned with methodical aspects of the development of bioinformatics approaches to the selection of candidate diagnostically informative DNA methylation sites. Since many highly correlated sites are excluded from the model during selection and since the resulting number of model sites is limited, the remaining model sites may not always represent the actual biological mechanisms associated with the disease. Despite this fact, we analyzed the possible functional role of the alterations in the genes included in the final model (<xref rid="pone.0204371.t002" ref-type="table">Table 2</xref>). For most of these genes, the available information suggests that they may play a role in the pathogenesis of oncological diseases.</p><p>For example, <italic>PRKCZ</italic> codes for the isoform of protein kinase C involved in a variety of cellular processes, such as proliferation, differentiation and secretion. This gene is best known as being responsible for insulin-stimulated glucose transport. Cornford et al. were the first to show that the protein kinase C gene (PKC)-zeta (<italic>PRKCZ</italic>) mediates the malignant phenotype of human prostate cancer [<xref rid="pone.0204371.ref052" ref-type="bibr">52</xref>]. Recently, a splice variant of <italic>PRKCZ</italic> has also been shown to be a novel biomarker of human prostate cancer [<xref rid="pone.0204371.ref053" ref-type="bibr">53</xref>]. <italic>PRKCZ</italic> has also been characterized as one of four genes with higher autoantibody titers in PC and is considered a novel potential serological prostate cancer biomarker [<xref rid="pone.0204371.ref054" ref-type="bibr">54</xref>]. The role of <italic>PRKCZ</italic> methylation in the pathogenesis of type 2 diabetes [<xref rid="pone.0204371.ref055" ref-type="bibr">55</xref>] and its association with sunlight exposure in North Americans [<xref rid="pone.0204371.ref056" ref-type="bibr">56</xref>] are being discussed, but to date, there is no evidence of the contribution of <italic>PRKCZ</italic> methylation to prostate cancer pathogenesis.</p><p><italic>EFEMP1</italic> was previously characterized as a biomarker for prostate cancer, for which epigenetic alteration occurs early in prostate carcinogenesis and, in association with histone deacetylation, progressively leads to gene down-regulation, fostering cell proliferation, invasion and evasion of apoptosis [<xref rid="pone.0204371.ref057" ref-type="bibr">57</xref>].</p><p>Decreased expression of the Fyn-associated substrate (<italic>EFS</italic>) gene involved in cell attachment is often associated with systemic recurrence of prostate cancer [<xref rid="pone.0204371.ref058" ref-type="bibr">58</xref>]. The association between <italic>EFS</italic> methylation and a considerable decrease in expression level in prostate cancer has also been observed [<xref rid="pone.0204371.ref059" ref-type="bibr">59</xref>]. The authors suppose that high <italic>EFS</italic> expression is important to suppress the malignant behavior of prostate cancer cells.</p><p>Many large-scale studies have reported an association between PC and methylation alterations in the <italic>GRASP</italic> gene coding for a general receptor for phosphoinositide-1-associated scaffold protein [<xref rid="pone.0204371.ref060" ref-type="bibr">60</xref>]. Further research concerning histologically benign prostate biopsy cores from cancer patients suggests that this marker is more likely to be methylated in histologically detectable cancer and may represent later events [<xref rid="pone.0204371.ref061" ref-type="bibr">61</xref>].</p><p>The <italic>NFATC3</italic> (nuclear factor of activated T-cells, cytoplasmic 3) gene plays a role in the regulation of gene expression in T cells and immature thymocytes. This gene is a member of the Wnt pathway and is associated with an increased risk of disease progression independent of clinical parameters among 7 other loci in an epithelial ovarian cancer model. Increased methylation at <italic>NFATC3</italic> is correlated with a poor response [<xref rid="pone.0204371.ref062" ref-type="bibr">62</xref>].</p><p>Although there is no solid evidence of association between C2orf88 methylation and prostate cancer, a study of colorectal cancer via integrative epigenomics and genomic data reported <italic>C2orf88</italic> to be among the 10 most significant differentially downregulated genes [<xref rid="pone.0204371.ref063" ref-type="bibr">63</xref>].</p><p>Therefore, we conclude that CpG sites included in the model lie within genes that have already been shown to contribute to the pathogenesis of PC or other types of oncological diseases.</p></sec><sec id="sec019"><title>Framework application for other cancers</title><p>The suggested framework for the selection of diagnostically informative methylation sites can also be used for oncological diseases other than prostate cancer. To estimate LogLoss-BERAF performance for other types of cancer, we applied it to available DNA methylation data for kidney, bladder and colorectal cancer. The choice of urological cancer was determined by the fact that these cancers are often characterized by the presence of tumor cells in urine. As analysis of urine samples is one of the promising non-invasive methods for PC diagnostics, such a test would allow an additional specificity test of the prostate cancer model applied for the differential diagnosis of other urological cancers. The choice of colorectal cancer data is in turn explained by its co-localization with PC. Although patients with synchronous carcinoma of the bladder and colon or rectum are rare, there is a possibility of sample contamination with colon cellular material, including malignantly transformed cells, during a transrectal biopsy.</p><p>LogLoss-BERAF was applied to the available datasets (<xref rid="pone.0204371.t001" ref-type="table">Table 1</xref>) for the listed cancers to select model and correlated methylation sites, and their diagnostic efficacy was estimated (Tables <xref rid="pone.0204371.t003" ref-type="table">3</xref> and <xref rid="pone.0204371.t004" ref-type="table">4</xref>, <xref ref-type="supplementary-material" rid="pone.0204371.s006">S5</xref>&#x02013;<xref ref-type="supplementary-material" rid="pone.0204371.s009">S8</xref> Tables).</p><table-wrap id="pone.0204371.t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0204371.t003</object-id><label>Table 3</label><caption><title>Model classification efficacy metrics: precision, recall, F1-score and AUC for test sets and the number of sites per model obtained using LogLoss-BERAF for different types of oncological diseases.</title></caption><alternatives><graphic id="pone.0204371.t003g" xlink:href="pone.0204371.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="justify" rowspan="1" colspan="1">Cancer type</th><th align="justify" rowspan="1" colspan="1">Sites num.</th><th align="justify" rowspan="1" colspan="1">Precision</th><th align="justify" rowspan="1" colspan="1">Recall</th><th align="justify" rowspan="1" colspan="1">F1 score</th><th align="justify" rowspan="1" colspan="1">AUC</th></tr></thead><tbody><tr><td align="justify" rowspan="1" colspan="1"><bold>Prostate Cancer</bold></td><td align="justify" rowspan="1" colspan="1">9</td><td align="justify" rowspan="1" colspan="1">0.95</td><td align="justify" rowspan="1" colspan="1">0.95</td><td align="justify" rowspan="1" colspan="1">0.95</td><td align="justify" rowspan="1" colspan="1">0.97</td></tr><tr><td align="justify" rowspan="1" colspan="1"><bold>Colorectal Cancer</bold></td><td align="justify" rowspan="1" colspan="1">3</td><td align="justify" rowspan="1" colspan="1">1.0</td><td align="justify" rowspan="1" colspan="1">1.0</td><td align="justify" rowspan="1" colspan="1">1.0</td><td align="justify" rowspan="1" colspan="1">1.0</td></tr><tr><td align="justify" rowspan="1" colspan="1"><bold>Bladder Cancer</bold></td><td align="justify" rowspan="1" colspan="1">6</td><td align="justify" rowspan="1" colspan="1">0.98</td><td align="justify" rowspan="1" colspan="1">0.98</td><td align="justify" rowspan="1" colspan="1">0.98</td><td align="justify" rowspan="1" colspan="1">1.0</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Kidney Cancer (KIRP)</bold></td><td align="justify" rowspan="1" colspan="1">5</td><td align="justify" rowspan="1" colspan="1">0.98</td><td align="justify" rowspan="1" colspan="1">0.98</td><td align="justify" rowspan="1" colspan="1">0.98</td><td align="justify" rowspan="1" colspan="1">1.0</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Kidney Cancer (KIRC)</bold></td><td align="justify" rowspan="1" colspan="1">2</td><td align="justify" rowspan="1" colspan="1">0.99</td><td align="justify" rowspan="1" colspan="1">0.99</td><td align="justify" rowspan="1" colspan="1">0.99</td><td align="justify" rowspan="1" colspan="1">1.0&#x000a0;</td></tr></tbody></table></alternatives></table-wrap><table-wrap id="pone.0204371.t004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0204371.t004</object-id><label>Table 4</label><caption><title>Co-localized and diagnostically similar cancers: classification of model sites with their positions and corresponding gene names and groups.</title></caption><alternatives><graphic id="pone.0204371.t004g" xlink:href="pone.0204371.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="justify" rowspan="1" colspan="1">IlmnID</th><th align="justify" rowspan="1" colspan="1">Chr</th><th align="justify" rowspan="1" colspan="1">Position</th><th align="justify" rowspan="1" colspan="1">Gene name</th><th align="justify" rowspan="1" colspan="1">Group</th></tr></thead><tbody><tr><td align="center" colspan="5" rowspan="1"><bold>Colon Adenocarcinoma</bold></td></tr><tr><td align="justify" rowspan="1" colspan="1">cg01588438</td><td align="justify" rowspan="1" colspan="1">chr8</td><td align="justify" rowspan="1" colspan="1">67344553</td><td align="justify" rowspan="1" colspan="1">ADHFE1</td><td align="justify" rowspan="1" colspan="1">TSS200</td></tr><tr><td align="justify" rowspan="1" colspan="1">cg04456219</td><td align="justify" rowspan="1" colspan="1">chr7</td><td align="justify" rowspan="1" colspan="1">17274337</td><td align="justify" rowspan="1" colspan="1">-</td><td align="justify" rowspan="1" colspan="1">-</td></tr><tr><td align="justify" rowspan="1" colspan="1">cg09287864</td><td align="justify" rowspan="1" colspan="1">chr7</td><td align="justify" rowspan="1" colspan="1">17274056</td><td align="justify" rowspan="1" colspan="1">-</td><td align="justify" rowspan="1" colspan="1">-</td></tr><tr><td align="center" colspan="5" rowspan="1"><bold>Urothelial Bladder Carcinoma</bold></td></tr><tr><td align="justify" rowspan="1" colspan="1">cg06830167</td><td align="justify" rowspan="1" colspan="1">chr1</td><td align="justify" rowspan="1" colspan="1">7600135</td><td align="justify" rowspan="1" colspan="1">CAMTA1</td><td align="justify" rowspan="1" colspan="1">Body</td></tr><tr><td align="justify" rowspan="1" colspan="1">cg10671066</td><td align="justify" rowspan="1" colspan="1">chr1</td><td align="justify" rowspan="1" colspan="1">160492861</td><td align="justify" rowspan="1" colspan="1">SLAMF6</td><td align="justify" rowspan="1" colspan="1">Body</td></tr><tr><td align="justify" rowspan="1" colspan="1">cg14357535</td><td align="justify" rowspan="1" colspan="1">chr2</td><td align="justify" rowspan="1" colspan="1">25389040</td><td align="justify" rowspan="1" colspan="1">POMC</td><td align="justify" rowspan="1" colspan="1">5'UTR</td></tr><tr><td align="justify" rowspan="1" colspan="1">cg03487935</td><td align="justify" rowspan="1" colspan="1">chr7</td><td align="justify" rowspan="1" colspan="1">51925284</td><td align="justify" rowspan="1" colspan="1">-</td><td align="justify" rowspan="1" colspan="1">-</td></tr><tr><td align="justify" rowspan="1" colspan="1">cg17202717</td><td align="justify" rowspan="1" colspan="1">chr7</td><td align="justify" rowspan="1" colspan="1">1708823</td><td align="justify" rowspan="1" colspan="1">-</td><td align="justify" rowspan="1" colspan="1">-</td></tr><tr><td align="justify" rowspan="1" colspan="1">cg01090433</td><td align="justify" rowspan="1" colspan="1">chr16</td><td align="justify" rowspan="1" colspan="1">82673506</td><td align="justify" rowspan="1" colspan="1">CDH13</td><td align="justify" rowspan="1" colspan="1">Body</td></tr><tr><td align="center" colspan="5" rowspan="1"><bold>Kidney Renal Clear Cell Carcinoma</bold></td></tr><tr><td align="justify" rowspan="1" colspan="1">cg22274117</td><td align="justify" rowspan="1" colspan="1">chr6</td><td align="justify" rowspan="1" colspan="1">16713613</td><td align="justify" rowspan="1" colspan="1">ATXN1</td><td align="justify" rowspan="1" colspan="1">5'UTR</td></tr><tr><td align="justify" rowspan="1" colspan="1">cg00347746</td><td align="justify" rowspan="1" colspan="1">chr19</td><td align="justify" rowspan="1" colspan="1">48970082</td><td align="justify" rowspan="1" colspan="1">-</td><td align="justify" rowspan="1" colspan="1">-</td></tr><tr><td align="center" colspan="5" rowspan="1"><bold>Kidney Renal Papillary Cell Carcinoma</bold></td></tr><tr><td align="justify" rowspan="1" colspan="1">cg04951371</td><td align="justify" rowspan="1" colspan="1">chr2</td><td align="justify" rowspan="1" colspan="1">3317860</td><td align="justify" rowspan="1" colspan="1">TSSC1</td><td align="justify" rowspan="1" colspan="1">Body</td></tr><tr><td align="justify" rowspan="1" colspan="1">cg22274117</td><td align="justify" rowspan="1" colspan="1">chr6</td><td align="justify" rowspan="1" colspan="1">16713613</td><td align="justify" rowspan="1" colspan="1">ATXN1</td><td align="justify" rowspan="1" colspan="1">5'UTR</td></tr><tr><td align="justify" rowspan="1" colspan="1">cg13458609</td><td align="justify" rowspan="1" colspan="1">chr9</td><td align="justify" rowspan="1" colspan="1">130608923</td><td align="justify" rowspan="1" colspan="1">ENG</td><td align="justify" rowspan="1" colspan="1">Body</td></tr><tr><td align="justify" rowspan="1" colspan="1">cg02921122</td><td align="justify" rowspan="1" colspan="1">chr10</td><td align="justify" rowspan="1" colspan="1">126712074</td><td align="justify" rowspan="1" colspan="1">CTBP2</td><td align="justify" rowspan="1" colspan="1">Body</td></tr><tr><td align="justify" rowspan="1" colspan="1">cg02766539</td><td align="justify" rowspan="1" colspan="1">chr17</td><td align="justify" rowspan="1" colspan="1">57861641</td><td align="justify" rowspan="1" colspan="1">TMEM49</td><td align="justify" rowspan="1" colspan="1">Body</td></tr></tbody></table></alternatives></table-wrap><p>Because of the small number of non-tumor samples in the urothelial bladder carcinoma dataset, 167 non-tumor samples from the kidney cancer dataset were added to the dataset before splitting into train and test subsets. The usage of methylation data from non-malignant tissues of other organs of the urogenital system is acceptable because tumors of this type represent a transitional epithelium carcinoma that affects the renal pelvis, renal ducts, bladder and urethra.</p><p>Classification efficacy of the resulting models was very high (<xref ref-type="fig" rid="pone.0204371.g004">Fig 4</xref>), and classification quality metrics, such as precision, recall, F1-score and the AUC for the test sets of the listed cancers, were higher than those for the prostate cancer model (<xref rid="pone.0204371.t003" ref-type="table">Table 3</xref>). It should be noted that the resulting models included fewer sites (<xref rid="pone.0204371.t004" ref-type="table">Table 4</xref>) and fewer correlated sites (<xref ref-type="supplementary-material" rid="pone.0204371.s006">S5</xref>&#x02013;<xref ref-type="supplementary-material" rid="pone.0204371.s009">S8</xref> Tables), indicating lower heterogeneity in these cancers compared to PC. The resulting models are specific and do not intersect with each other at the level of model and correlated sites, with the exception of <italic>cg22274117</italic> in the <italic>ATXN1</italic> gene (Kidney Carcinoma model). The analysis of these sites showed that they were previously reported as potential diagnostic biomarkers. The hypermethylation of the <italic>ADHFE1</italic> promoter in colorectal cancer has recently been demonstrated [<xref rid="pone.0204371.ref064" ref-type="bibr">64</xref>,<xref rid="pone.0204371.ref065" ref-type="bibr">65</xref>]. <italic>CDH13</italic> promoter methylation has been identified as a biomarker for bladder cancer [<xref rid="pone.0204371.ref066" ref-type="bibr">66</xref>]. Recently, <italic>ENG</italic> promoter hypermethylation was reported in several human cancers [<xref rid="pone.0204371.ref067" ref-type="bibr">67</xref>&#x02013;<xref rid="pone.0204371.ref069" ref-type="bibr">69</xref>]. These results suggest that the LogLoss-BERAF framework could be effectively applied to different classification tasks.</p><fig id="pone.0204371.g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0204371.g004</object-id><label>Fig 4</label><caption><title>ROC curves for prostate adenocarcinoma (red), colon adenocarcinoma (yellow), urothelial bladder carcinoma (green), kidney renal papillary cell carcinoma (purple) and kidney renal clear cell carcinoma (blue) models.</title><p>The lower-right inset shows a close-up of the upper-left parts of the AUC curves.</p></caption><graphic xlink:href="pone.0204371.g004"/></fig></sec></sec><sec sec-type="conclusions" id="sec020"><title>Conclusion</title><p>We have designed a framework for selection of a limited number of informative DNA methylation sites based on a combination of several feature selection methods and an ensemble-based classifier. We have applied the algorithm to the task of prostate cancer diagnostics and constructed a model with high classification efficacy metrics: 0.95 recall, 0.95 precision and 0.97 AUC. The method has also been demonstrated for methylation data from other types of cancers that are either co-localized with PC (colorectal cancer) or can be diagnosed using similar biological urine samples (bladder and kidney cancers), yielding model AUC values of 1.0. Based on the panel methylation pattern variability, a cluster of cancer samples was shown to have statistically significant higher recurrence rate. The resulting model has demonstrated robustness against input data errors, which can potentially allow the utilization of methylation level detection using other experimental strategies with lower resolution. The biological significance of the identified sites has been confirmed by previous studies.</p></sec><sec sec-type="supplementary-material" id="sec021"><title>Supporting information</title><supplementary-material content-type="local-data" id="pone.0204371.s001"><label>S1 Fig</label><caption><title>Methylation level distribution for 9 sites from PRAD diagnostic model constructed on the basis of the whole PRAD subset (<xref rid="pone.0204371.t001" ref-type="table">Table 1</xref>).</title><p>The dashed lines correspond to 95 and 5 quartiles, distribution medians are shown in red. Y axis shows methylation &#x003b2;-value.</p><p>(DOCX)</p></caption><media xlink:href="pone.0204371.s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0204371.s002"><label>S1 Table</label><caption><title>Sample selection criteria for subsequent PRAD model construction.</title><p>(XLSX)</p></caption><media xlink:href="pone.0204371.s002.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0204371.s003"><label>S2 Table</label><caption><title>Methylation level values for the sites of the resulting PRAD model.</title><p>(XLSX)</p></caption><media xlink:href="pone.0204371.s003.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0204371.s004"><label>S3 Table</label><caption><title>Classification efficacy of tumor and non-tumor samples by PRAD gene and site methylation data analysis for different studies.</title><p>(XLSX)</p></caption><media xlink:href="pone.0204371.s004.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0204371.s005"><label>S4 Table</label><caption><title>PRAD model list of correlated sites.</title><p>(XLSX)</p></caption><media xlink:href="pone.0204371.s005.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0204371.s006"><label>S5 Table</label><caption><title>KIRC model list of correlated sites.</title><p>(XLSX)</p></caption><media xlink:href="pone.0204371.s006.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0204371.s007"><label>S6 Table</label><caption><title>KIRP model list of correlated sites.</title><p>(XLSX)</p></caption><media xlink:href="pone.0204371.s007.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0204371.s008"><label>S7 Table</label><caption><title>BLCA model list of correlated sites.</title><p>(XLSX)</p></caption><media xlink:href="pone.0204371.s008.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0204371.s009"><label>S8 Table</label><caption><title>CRCA model list of correlated sites.</title><p>(XLSX)</p></caption><media xlink:href="pone.0204371.s009.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list><title>References</title><ref id="pone.0204371.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Ferlay</surname><given-names>J</given-names></name>, <name><surname>Soerjomataram</surname><given-names>I</given-names></name>, <name><surname>Dikshit</surname><given-names>R</given-names></name>, <name><surname>Eser</surname><given-names>S</given-names></name>, <name><surname>Mathers</surname><given-names>C</given-names></name>, <name><surname>Rebelo</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012</article-title>. <source>Int J Cancer</source>. <year>2015</year>;<volume>136</volume>: <fpage>E359</fpage>&#x02013;<lpage>E386</lpage>. <pub-id pub-id-type="doi">10.1002/ijc.29210</pub-id>
<?supplied-pmid 25220842?><pub-id pub-id-type="pmid">25220842</pub-id></mixed-citation></ref><ref id="pone.0204371.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Ciccarese</surname><given-names>C</given-names></name>, <name><surname>Massari</surname><given-names>F</given-names></name>, <name><surname>Iacovelli</surname><given-names>R</given-names></name>, <name><surname>Fiorentino</surname><given-names>M</given-names></name>, <name><surname>Montironi</surname><given-names>R</given-names></name>, <name><surname>Di Nunno</surname><given-names>V</given-names></name>, <etal>et al</etal>
<article-title>Prostate cancer heterogeneity: Discovering novel molecular targets for therapy</article-title>. <source>Cancer Treat Rev. Elsevier Ltd</source>; <year>2017</year>;<volume>54</volume>: <fpage>68</fpage>&#x02013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1016/j.ctrv.2017.02.001</pub-id>
<?supplied-pmid 28231559?><pub-id pub-id-type="pmid">28231559</pub-id></mixed-citation></ref><ref id="pone.0204371.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Bijnsdorp</surname><given-names>I V.</given-names></name>, <name><surname>van Royen</surname><given-names>ME</given-names></name>, <name><surname>Verhaegh</surname><given-names>GW</given-names></name>, <name><surname>Martens-Uzunova</surname><given-names>ES</given-names></name>. <article-title>The Non-Coding Transcriptome of Prostate Cancer: Implications for Clinical Practice</article-title>. <source>Mol Diagn Ther</source>. Springer International Publishing; <year>2017</year>;<volume>21</volume>: <fpage>385</fpage>&#x02013;<lpage>400</lpage>. <pub-id pub-id-type="doi">10.1007/s40291-017-0271-2</pub-id>
<?supplied-pmid 28299719?><pub-id pub-id-type="pmid">28299719</pub-id></mixed-citation></ref><ref id="pone.0204371.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>LC</given-names></name>. <article-title>Epigenetics of prostate cancer</article-title>. <source>Front Biosci</source>. <year>2007</year>;<fpage>12</fpage>.</mixed-citation></ref><ref id="pone.0204371.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Berdasco</surname><given-names>M</given-names></name>, <name><surname>Esteller</surname><given-names>M</given-names></name>. <article-title>Aberrant Epigenetic Landscape in Cancer: How Cellular Identity Goes Awry</article-title>. <source>Dev Cell</source>. <year>2010</year>;<volume>19</volume>: <fpage>698</fpage>&#x02013;<lpage>711</lpage>. <pub-id pub-id-type="doi">10.1016/j.devcel.2010.10.005</pub-id>
<?supplied-pmid 21074720?><pub-id pub-id-type="pmid">21074720</pub-id></mixed-citation></ref><ref id="pone.0204371.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Giacinti</surname><given-names>L</given-names></name>, <name><surname>Vici</surname><given-names>P LM</given-names></name>. <article-title>Epigenome: a new target in cancer therapy</article-title>. <source>Clin Ter</source>. <year>2008</year>;<season>Sep-Oct</season>;<volume>15</volume>: <fpage>347</fpage>&#x02013;<lpage>360</lpage>.</mixed-citation></ref><ref id="pone.0204371.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Bibikova</surname><given-names>M</given-names></name>, <name><surname>Barnes</surname><given-names>B</given-names></name>, <name><surname>Tsan</surname><given-names>C</given-names></name>, <name><surname>Ho</surname><given-names>V</given-names></name>, <name><surname>Klotzle</surname><given-names>B</given-names></name>, <name><surname>Le</surname><given-names>JM</given-names></name>, <etal>et al</etal>
<article-title>High density DNA methylation array with single CpG site resolution</article-title>. <source>Genomics</source>. Elsevier Inc.; <year>2011</year>;<volume>98</volume>: <fpage>288</fpage>&#x02013;<lpage>295</lpage>. <pub-id pub-id-type="doi">10.1016/j.ygeno.2011.07.007</pub-id>
<?supplied-pmid 21839163?><pub-id pub-id-type="pmid">21839163</pub-id></mixed-citation></ref><ref id="pone.0204371.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Hessels</surname><given-names>D</given-names></name>, <name><surname>Schalken</surname><given-names>JA</given-names></name>. <article-title>Urinary biomarkers for prostate cancer: a review</article-title>. <source>Asian J Androl</source>. <year>2013</year>;<volume>15</volume>: <fpage>333</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/aja.2013.6</pub-id>
<?supplied-pmid 23524531?><pub-id pub-id-type="pmid">23524531</pub-id></mixed-citation></ref><ref id="pone.0204371.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Pisanic</surname><given-names>T</given-names></name>, <name><surname>Athamanolap</surname><given-names>P</given-names></name>, <name><surname>Wang</surname><given-names>T-H</given-names></name>. <article-title>Defining, distinguishing and detecting the contribution of heterogeneous methylation to cancer heterogeneity</article-title>. <source>Semin Cell Dev Biol</source>. Elsevier Ltd; <year>2016</year>; <pub-id pub-id-type="doi">10.1016/j.matchemphys.2008.10.020</pub-id></mixed-citation></ref><ref id="pone.0204371.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Ma</surname><given-names>SS</given-names></name>. <article-title>Integrative analysis of cancer genomic data</article-title>. <year>2006</year>; <fpage>82</fpage>&#x02013;<lpage>90</lpage>.</mixed-citation></ref><ref id="pone.0204371.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Teschendorff</surname><given-names>AE</given-names></name>, <name><surname>Widschwendter</surname><given-names>M</given-names></name>. <article-title>Differential variability improves the identification of cancer risk markers in DNA methylation studies profiling precursor cancer lesions</article-title>. <source>Bioinformatics</source>. <year>2012</year>;<volume>28</volume>: <fpage>1487</fpage>&#x02013;<lpage>1494</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/bts170</pub-id>
<?supplied-pmid 22492641?><pub-id pub-id-type="pmid">22492641</pub-id></mixed-citation></ref><ref id="pone.0204371.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Blum</surname><given-names>AL</given-names></name>, <name><surname>Langley</surname><given-names>P</given-names></name>. <article-title>Selection of relevant features and examples in machine learning</article-title>. <source>Artif Intell</source>. <year>1997</year>;<volume>97</volume>: <fpage>245</fpage>&#x02013;<lpage>271</lpage>. <pub-id pub-id-type="doi">10.1016/S0004-3702(97)00063-5</pub-id></mixed-citation></ref><ref id="pone.0204371.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Tibshirani</surname><given-names>R.</given-names></name> the <article-title>Lasso Method for Variable Selection in the Cox Model</article-title>. <year>1997</year>;<volume>16</volume>: <fpage>385</fpage>&#x02013;<lpage>395</lpage>. <pub-id pub-id-type="doi">10.1002/(SICI)1097-0258(19970228)16:4&#x0003c;385::AID-SIM380&#x0003e;3.0.CO;2&#x02013;3</pub-id>
<?supplied-pmid 9044528?><pub-id pub-id-type="pmid">9044528</pub-id></mixed-citation></ref><ref id="pone.0204371.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Chuang</surname><given-names>L-Y</given-names></name>, <name><surname>Chang</surname><given-names>H-W</given-names></name>, <name><surname>Tu</surname><given-names>C-J</given-names></name>, <name><surname>Yang</surname><given-names>C-H</given-names></name>. <article-title>Improved binary PSO for feature selection using gene expression data</article-title>. <source>Comput Biol Chem</source>. <year>2008</year>;<volume>32</volume>: <fpage>29</fpage>&#x02013;<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1016/j.compbiolchem.2007.09.005</pub-id>
<?supplied-pmid 18023261?><pub-id pub-id-type="pmid">18023261</pub-id></mixed-citation></ref><ref id="pone.0204371.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Ding</surname><given-names>C</given-names></name>, <name><surname>Peng</surname><given-names>H</given-names></name>. <article-title>Minimum redundancy feature selection from microarray gene expression data</article-title>. <source>J Bioinforma Comput</source> &#x02026;. <year>2005</year>;<volume>3</volume>: <fpage>185</fpage>&#x02013;<lpage>205</lpage>. <pub-id pub-id-type="doi">10.1142/S0219720005001004</pub-id></mixed-citation></ref><ref id="pone.0204371.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Lazar</surname><given-names>C</given-names></name>, <name><surname>Taminau</surname><given-names>J</given-names></name>, <name><surname>Meganck</surname><given-names>S</given-names></name>, <name><surname>Steenhoff</surname><given-names>D</given-names></name>, <name><surname>Coletta</surname><given-names>A</given-names></name>, <name><surname>Molter</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>A survey on filter techniques for feature selection in gene expression microarray analysis</article-title>. <source>IEEE/ACM Trans Comput Biol Bioinform</source>. <year>2012</year>;<volume>9</volume>: <fpage>1106</fpage>&#x02013;<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1109/TCBB.2012.33</pub-id>
<?supplied-pmid 22350210?><pub-id pub-id-type="pmid">22350210</pub-id></mixed-citation></ref><ref id="pone.0204371.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Puthiyedth</surname><given-names>N</given-names></name>, <name><surname>Riveros</surname><given-names>C</given-names></name>, <name><surname>Berretta</surname><given-names>R</given-names></name>, <name><surname>Moscato</surname><given-names>P</given-names></name>. <article-title>A New Combinatorial Optimization Approach for Integrated Feature Selection Using Different Datasets: A Prostate Cancer Transcriptomic Study</article-title>. <source>PLoS One</source>. <year>2015</year>;<volume>10</volume>: <fpage>e0127702</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0127702</pub-id>
<?supplied-pmid 26106884?><pub-id pub-id-type="pmid">26106884</pub-id></mixed-citation></ref><ref id="pone.0204371.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Radovic</surname><given-names>M</given-names></name>, <name><surname>Ghalwash</surname><given-names>M</given-names></name>, <name><surname>Filipovic</surname><given-names>N</given-names></name>, <name><surname>Obradovic</surname><given-names>Z</given-names></name>. <article-title>Minimum redundancy maximum relevance feature selection approach for temporal gene expression data</article-title>. <source>BMC Bioinformatics. BMC Bioinformatics</source>; <year>2017</year>; <fpage>1</fpage>&#x02013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1186/s12859-016-1414-x</pub-id><pub-id pub-id-type="pmid">28049414</pub-id></mixed-citation></ref><ref id="pone.0204371.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Wilin</surname><given-names>A.</given-names></name>
<article-title>Gene selection for cancer classification</article-title>. <year>2009</year>; <fpage>389</fpage>&#x02013;<lpage>422</lpage>. <pub-id pub-id-type="doi">10.1108/03321640910919020</pub-id></mixed-citation></ref><ref id="pone.0204371.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Labuzzetta</surname><given-names>CJ</given-names></name>, <name><surname>Antonio</surname><given-names>ML</given-names></name>, <name><surname>Watson</surname><given-names>PM</given-names></name>, <name><surname>Wilson</surname><given-names>RC</given-names></name>, <name><surname>Laboissonniere</surname><given-names>LA</given-names></name>, <name><surname>Trimarchi</surname><given-names>JM</given-names></name>, <etal>et al</etal>
<article-title>Complementary feature selection from alternative splicing events and gene expression for phenotype prediction</article-title>. <source>Bioinformatics</source>. <year>2016</year>;<volume>32</volume>: <fpage>i421</fpage>&#x02013;<lpage>i429</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btw430</pub-id>
<?supplied-pmid 27587658?><pub-id pub-id-type="pmid">27587658</pub-id></mixed-citation></ref><ref id="pone.0204371.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Calle</surname><given-names>ML</given-names></name>, <name><surname>Urrea</surname><given-names>V</given-names></name>, <name><surname>Boulesteix</surname><given-names>AL</given-names></name>, <name><surname>Malats</surname><given-names>N</given-names></name>. <article-title>AUC-RF: A new strategy for genomic profiling with random forest</article-title>. <source>Hum Hered</source>. <year>2011</year>;<volume>72</volume>: <fpage>121</fpage>&#x02013;<lpage>132</lpage>. <pub-id pub-id-type="doi">10.1159/000330778</pub-id>
<?supplied-pmid 21996641?><pub-id pub-id-type="pmid">21996641</pub-id></mixed-citation></ref><ref id="pone.0204371.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>De Maturana</surname><given-names>EL</given-names></name>, <name><surname>Ye</surname><given-names>Y</given-names></name>, <name><surname>Calle</surname><given-names>ML</given-names></name>, <name><surname>Rothman</surname><given-names>N</given-names></name>, <name><surname>Urrea</surname><given-names>V</given-names></name>, <name><surname>Kogevinas</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Application of multi-SNP approaches Bayesian LASSO and AUC-RF to detect main effects of inflammatory-gene variants associated with bladder cancer risk</article-title>. <source>PLoS One</source>. <year>2013</year>;<fpage>8</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0083745</pub-id>
<?supplied-pmid 24391818?><pub-id pub-id-type="pmid">24391818</pub-id></mixed-citation></ref><ref id="pone.0204371.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Alkuhlani</surname><given-names>A</given-names></name>, <name><surname>Nassef</surname><given-names>M</given-names></name>, <name><surname>Farag</surname><given-names>I</given-names></name>. <article-title>Multistage feature selection approach for high-dimensional cancer data</article-title>. <source>Soft Comput</source>. Springer Berlin Heidelberg; <year>2016</year>; <pub-id pub-id-type="doi">10.1007/s00500-016-2439-9</pub-id></mixed-citation></ref><ref id="pone.0204371.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>MA</surname><given-names>Z</given-names></name>, <name><surname>TESCHENDORFF</surname><given-names>AE</given-names></name>. <article-title>a Variational Bayes Beta Mixture Model for Feature Selection in Dna Methylation Studies</article-title>. <source>J Bioinform Comput Biol</source>. <year>2013</year>;<volume>11</volume>: <fpage>1350005</fpage>
<pub-id pub-id-type="doi">10.1142/S0219720013500054</pub-id>
<?supplied-pmid 23859269?><pub-id pub-id-type="pmid">23859269</pub-id></mixed-citation></ref><ref id="pone.0204371.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Bibikova</surname><given-names>M</given-names></name>, <name><surname>Le</surname><given-names>J</given-names></name>, <name><surname>Barnes</surname><given-names>B</given-names></name>, <name><surname>Saedinia-Melnyk</surname><given-names>S</given-names></name>, <name><surname>Zhou</surname><given-names>L</given-names></name>, <name><surname>Shen</surname><given-names>R</given-names></name>, <etal>et al</etal>
<article-title>Genome-wide DNA methylation profiling using Infinium assay</article-title>. <source>Epigenomics</source>. <year>2009</year>;<volume>1</volume>: <fpage>177</fpage>&#x02013;<lpage>200</lpage>. <pub-id pub-id-type="doi">10.2217/epi.09.14</pub-id>
<?supplied-pmid 22122642?><pub-id pub-id-type="pmid">22122642</pub-id></mixed-citation></ref><ref id="pone.0204371.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Chihara</surname><given-names>Y</given-names></name>, <name><surname>Kanai</surname><given-names>Y</given-names></name>, <name><surname>Fujimoto</surname><given-names>H</given-names></name>, <name><surname>Sugano</surname><given-names>K</given-names></name>, <name><surname>Kawashima</surname><given-names>K</given-names></name>, <name><surname>Liang</surname><given-names>G</given-names></name>, <etal>et al</etal>
<article-title>Diagnostic markers of urothelial cancer based on DNA methylation analysis</article-title>. <source>BMC Cancer</source>. <year>2013</year>;<volume>13</volume>: <fpage>275</fpage>
<pub-id pub-id-type="doi">10.1186/1471-2407-13-275</pub-id>
<?supplied-pmid 23735005?><pub-id pub-id-type="pmid">23735005</pub-id></mixed-citation></ref><ref id="pone.0204371.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Majer</surname><given-names>W</given-names></name>, <name><surname>Kluzek</surname><given-names>K</given-names></name>, <name><surname>Bluyssen</surname><given-names>H</given-names></name>, <name><surname>Wesoly</surname><given-names>J</given-names></name>. <article-title>Potential approaches and recent advances in biomarker discovery in clear-cell Renal Cell Carcinoma</article-title>. <source>J Cancer</source>. <year>2015</year>;<volume>6</volume>: <fpage>1105</fpage>&#x02013;<lpage>1113</lpage>. <pub-id pub-id-type="doi">10.7150/jca.12145</pub-id>
<?supplied-pmid 26516358?><pub-id pub-id-type="pmid">26516358</pub-id></mixed-citation></ref><ref id="pone.0204371.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Assenov</surname><given-names>Y</given-names></name>, <name><surname>M&#x000fc;ller</surname><given-names>F</given-names></name>, <name><surname>Lutsik</surname><given-names>P</given-names></name>, <name><surname>Walter</surname><given-names>J</given-names></name>, <name><surname>Lengauer</surname><given-names>T</given-names></name>, <name><surname>Bock</surname><given-names>C</given-names></name>. <article-title>Comprehensive analysis of DNA methylation data with RnBeads</article-title>. <year>2014</year>; <pub-id pub-id-type="doi">10.1038/nmeth.3115</pub-id>
<?supplied-pmid 25262207?><pub-id pub-id-type="pmid">25262207</pub-id></mixed-citation></ref><ref id="pone.0204371.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Leek</surname><given-names>JT</given-names></name>, <name><surname>Johnson</surname><given-names>WE</given-names></name>, <name><surname>Parker</surname><given-names>HS</given-names></name>, <name><surname>Jaffe</surname><given-names>AE</given-names></name>, <name><surname>Storey</surname><given-names>JD</given-names></name>. <article-title>The sva package for removing batch effects and other unwanted variation in high-throughput experiments</article-title>. <year>2012</year>;<volume>28</volume>: <fpage>882</fpage>&#x02013;<lpage>883</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/bts034</pub-id>
<?supplied-pmid 22257669?><pub-id pub-id-type="pmid">22257669</pub-id></mixed-citation></ref><ref id="pone.0204371.ref030"><label>30</label><mixed-citation publication-type="journal">Jr TJT, <name><surname>Weisenberger</surname><given-names>DJ</given-names></name>, <name><surname>Berg</surname><given-names>D Van Den</given-names></name>, <name><surname>Laird</surname><given-names>PW</given-names></name>, <name><surname>Siegmund</surname><given-names>KD</given-names></name>. <article-title>Low-level processing of Illumina Infinium DNA Methylation BeadArrays</article-title>. <year>2013</year>;<volume>41</volume>: <fpage>1</fpage>&#x02013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkt090</pub-id>
<?supplied-pmid 23476028?><pub-id pub-id-type="pmid">23476028</pub-id></mixed-citation></ref><ref id="pone.0204371.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Teschendorff</surname><given-names>AE</given-names></name>, <name><surname>Marabita</surname><given-names>F</given-names></name>, <name><surname>Lechner</surname><given-names>M</given-names></name>, <name><surname>Bartlett</surname><given-names>T</given-names></name>, <name><surname>Tegner</surname><given-names>J</given-names></name>, <name><surname>Gomez-cabrero</surname><given-names>D</given-names></name>, <etal>et al</etal>
<article-title>Gene expression A beta-mixture quantile normalization method for correcting probe design bias in Illumina Infinium 450 k DNA methylation data</article-title>. <year>2013</year>;<volume>29</volume>: <fpage>189</fpage>&#x02013;<lpage>196</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/bts680</pub-id>
<?supplied-pmid 23175756?><pub-id pub-id-type="pmid">23175756</pub-id></mixed-citation></ref><ref id="pone.0204371.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>J</given-names></name>, <name><surname>Siegmund</surname><given-names>KD</given-names></name>. <article-title>An evaluation of processing methods for HumanMethylation450 BeadChip data</article-title>. <source>BMC Genomics</source>. BMC Genomics; <year>2016</year>; <fpage>1</fpage>&#x02013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1186/s12864-015-2294-6</pub-id><pub-id pub-id-type="pmid">26818753</pub-id></mixed-citation></ref><ref id="pone.0204371.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Meinshausen</surname><given-names>N.</given-names></name>
<article-title>Stability selection</article-title>. <year>2009</year>; <fpage>1</fpage>&#x02013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1111/j.1467-9868.2010.00740.x</pub-id></mixed-citation></ref><ref id="pone.0204371.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Pedregosa</surname><given-names>F</given-names></name>, <name><surname>Weiss</surname><given-names>R</given-names></name>, <name><surname>Brucher</surname><given-names>M</given-names></name>. <article-title>Scikit-learn: Machine Learning in Python</article-title>. <year>2011</year>;<volume>12</volume>: <fpage>2825</fpage>&#x02013;<lpage>2830</lpage>.</mixed-citation></ref><ref id="pone.0204371.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Breiman</surname><given-names>L.</given-names></name>
<article-title>Random Forests</article-title>. <source>Mach Learn</source>. <year>2001</year>;<volume>45</volume>(<issue>1</issue>): <fpage>5</fpage>&#x02013;<lpage>32</lpage>.</mixed-citation></ref><ref id="pone.0204371.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Rodr&#x000ed;guez</surname><given-names>JD</given-names></name>, <name><surname>P&#x000e9;rez</surname><given-names>A</given-names></name>, <name><surname>Lozano</surname><given-names>JA</given-names></name>. <article-title>A general framework for the statistical analysis of the sources of variance for classification error estimators</article-title>. <source>Pattern Recognit</source>. <year>2013</year>;<volume>46</volume>: <fpage>855</fpage>&#x02013;<lpage>864</lpage>. <pub-id pub-id-type="doi">10.1016/j.patcog.2012.09.007</pub-id></mixed-citation></ref><ref id="pone.0204371.ref037"><label>37</label><mixed-citation publication-type="book"><name><surname>Bishop</surname><given-names>CM</given-names></name>. <chapter-title>Pattern Recognition and Machine Learning</chapter-title>
<publisher-name>Springer</publisher-name>
<year>2006</year>; <volume>209</volume>.</mixed-citation></ref><ref id="pone.0204371.ref038"><label>38</label><mixed-citation publication-type="journal">K, <name><surname>O&#x00026;apos;Reilly</surname><given-names>KJ</given-names></name>, <name><surname>Hanson</surname><given-names>JC</given-names></name>, <name><surname>Nelson</surname><given-names>D</given-names></name>, <name><surname>Walk</surname><given-names>EL</given-names></name>, <name><surname>Tangrea</surname><given-names>JA</given-names></name>. <article-title>The usefulness of the detection of GSTP1 methylation in urine as a biomarker in the diagnosis of prostate cancer</article-title>. <source>J Urol</source>. <year>2008</year>;<volume>179</volume>: <fpage>508</fpage>&#x02013;<lpage>511</lpage>. <pub-id pub-id-type="doi">10.1016/j.juro.2007.09.073</pub-id>
<?supplied-pmid 18076912?><pub-id pub-id-type="pmid">18076912</pub-id></mixed-citation></ref><ref id="pone.0204371.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Nakayama</surname><given-names>M</given-names></name>, <name><surname>Gonzalgo</surname><given-names>ML</given-names></name>, <name><surname>Yegnasubramanian</surname><given-names>S</given-names></name>, <name><surname>Lin</surname><given-names>X</given-names></name>, <name><surname>De Marzo</surname><given-names>AM</given-names></name>, <name><surname>Nelson</surname><given-names>WG</given-names></name>. <article-title>GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer</article-title>. <source>J Cell Biochem</source>. <year>2004</year>;<volume>91</volume>: <fpage>540</fpage>&#x02013;<lpage>552</lpage>. <pub-id pub-id-type="doi">10.1002/jcb.10740</pub-id>
<?supplied-pmid 14755684?><pub-id pub-id-type="pmid">14755684</pub-id></mixed-citation></ref><ref id="pone.0204371.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Cairns</surname><given-names>P</given-names></name>, <name><surname>Esteller</surname><given-names>M</given-names></name>, <name><surname>Herman</surname><given-names>JG</given-names></name>, <name><surname>Schoenberg</surname><given-names>M</given-names></name>, <name><surname>Jeronimo</surname><given-names>C</given-names></name>, <name><surname>Chow</surname><given-names>N</given-names></name>, <etal>et al</etal>
<article-title>Molecular Detection of Prostate Cancer in Urine by GSTP1 Hypermethylation Molecular Detection of Prostate Cancer in Urine by GSTP1</article-title>. <year>2001</year>;<volume>7</volume>: <fpage>2727</fpage>&#x02013;<lpage>2730</lpage>. <?supplied-pmid 11555585?><pub-id pub-id-type="pmid">11555585</pub-id></mixed-citation></ref><ref id="pone.0204371.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Stewart</surname><given-names>GD</given-names></name>, <name><surname>Van Neste</surname><given-names>L</given-names></name>, <name><surname>Delvenne</surname><given-names>P</given-names></name>, <name><surname>Delr??e</surname><given-names>P</given-names></name>, <name><surname>Delga</surname><given-names>A</given-names></name>, <name><surname>McNeill</surname><given-names>SA</given-names></name>, <etal>et al</etal>
<article-title>Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: Results of the MATLOC study</article-title>. <source>J Urol. Elsevier Inc.</source>; <year>2013</year>;<volume>189</volume>: <fpage>1110</fpage>&#x02013;<lpage>1116</lpage>. <pub-id pub-id-type="doi">10.1016/j.juro.2012.08.219</pub-id>
<?supplied-pmid 22999998?><pub-id pub-id-type="pmid">22999998</pub-id></mixed-citation></ref><ref id="pone.0204371.ref042"><label>42</label><mixed-citation publication-type="journal"><name><surname>Chung</surname><given-names>W</given-names></name>, <name><surname>Kwabi-Addo</surname><given-names>B</given-names></name>, <name><surname>Ittmann</surname><given-names>M</given-names></name>, <name><surname>Jelinek</surname><given-names>J</given-names></name>, <name><surname>Shen</surname><given-names>L</given-names></name>, <name><surname>Yu</surname><given-names>Y</given-names></name>, <etal>et al</etal>
<article-title>Identification of novel tumor markers in prostate, colon and breast cancer by unbiased methylation profiling</article-title>. <source>PLoS One</source>. <year>2008</year>;<volume>3</volume>
<pub-id pub-id-type="doi">10.1371/journal.pone.0002079</pub-id>
<?supplied-pmid 18446232?><pub-id pub-id-type="pmid">18446232</pub-id></mixed-citation></ref><ref id="pone.0204371.ref043"><label>43</label><mixed-citation publication-type="journal"><name><surname>Kirby</surname><given-names>MK</given-names></name>, <name><surname>Ramaker</surname><given-names>RC</given-names></name>, <name><surname>Roberts</surname><given-names>BS</given-names></name>, <name><surname>Lasseigne</surname><given-names>BN</given-names></name>, <name><surname>Gunther</surname><given-names>DS</given-names></name>, <name><surname>Burwell</surname><given-names>TC</given-names></name>, <etal>et al</etal>
<article-title>Genome-wide DNA methylation measurements in prostate tissues uncovers novel prostate cancer diagnostic biomarkers and transcription factor binding patterns. BMC Cancer</article-title>. <source>BMC Cancer</source>; <year>2017</year>;<volume>17</volume>: <fpage>273</fpage>
<pub-id pub-id-type="doi">10.1186/s12885-017-3252-2</pub-id>
<?supplied-pmid 28412973?><pub-id pub-id-type="pmid">28412973</pub-id></mixed-citation></ref><ref id="pone.0204371.ref044"><label>44</label><mixed-citation publication-type="journal"><name><surname>Tang</surname><given-names>Y</given-names></name>, <name><surname>Jiang</surname><given-names>S</given-names></name>, <name><surname>Gu</surname><given-names>Y</given-names></name>, <name><surname>Li</surname><given-names>W</given-names></name>, <name><surname>Mo</surname><given-names>Z</given-names></name>. <article-title>Promoter DNA methylation analysis reveals a combined diagnosis of CpG-based biomarker for prostate cancer</article-title>. <year>2017</year>; <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.18632/oncotarget.16437">10.18632/oncotarget.16437</ext-link></comment>
<?supplied-pmid 28938548?><pub-id pub-id-type="pmid">28938548</pub-id></mixed-citation></ref><ref id="pone.0204371.ref045"><label>45</label><mixed-citation publication-type="journal"><name><surname>Ein-Dor</surname><given-names>L</given-names></name>, <name><surname>Kela</surname><given-names>I</given-names></name>, <name><surname>Getz</surname><given-names>G</given-names></name>, <name><surname>Givol</surname><given-names>D</given-names></name>, <name><surname>Domany</surname><given-names>E</given-names></name>. <article-title>Outcome signature genes in breast cancer: Is there a unique set?</article-title>
<source>Bioinformatics</source>. <year>2005</year>;<volume>21</volume>: <fpage>171</fpage>&#x02013;<lpage>178</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/bth469</pub-id>
<?supplied-pmid 15308542?><pub-id pub-id-type="pmid">15308542</pub-id></mixed-citation></ref><ref id="pone.0204371.ref046"><label>46</label><mixed-citation publication-type="journal"><name><surname>Cho</surname><given-names>SB</given-names></name>, <name><surname>Won</surname><given-names>H-H</given-names></name>. <article-title>Cancer classification using ensemble of neural networks with multiple significant gene subsets</article-title>. <source>Appl Intell</source>. <year>2006</year>;<volume>26</volume>: <fpage>243</fpage>&#x02013;<lpage>250</lpage>. <pub-id pub-id-type="doi">10.1007/s10489-006-0020-4</pub-id></mixed-citation></ref><ref id="pone.0204371.ref047"><label>47</label><mixed-citation publication-type="journal"><name><surname>Kuncheva</surname><given-names>LI</given-names></name>. <article-title>A stability index for feature selection</article-title>. <source>Int Multi-conference Artif Intell Appl</source>. <year>2007</year>; <fpage>390</fpage>&#x02013;<lpage>395</lpage>. Available: papers2://publication/uuid/FC5277DF-B494-4316-8D02-E8CE794BAE37</mixed-citation></ref><ref id="pone.0204371.ref048"><label>48</label><mixed-citation publication-type="journal"><name><surname>Abeshouse</surname><given-names>A</given-names></name>, <name><surname>Ahn</surname><given-names>J</given-names></name>, <name><surname>Akbani</surname><given-names>R</given-names></name>, <name><surname>Ally</surname><given-names>A</given-names></name>, <name><surname>Amin</surname><given-names>S</given-names></name>, <name><surname>Andry</surname><given-names>CD</given-names></name>, <etal>et al</etal>
<article-title>The Molecular Taxonomy of Primary Prostate Cancer</article-title>. <source>Cell</source>. <year>2015</year>;<volume>163</volume>: <fpage>1011</fpage>&#x02013;<lpage>1025</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2015.10.025</pub-id>
<?supplied-pmid 26544944?><pub-id pub-id-type="pmid">26544944</pub-id></mixed-citation></ref><ref id="pone.0204371.ref049"><label>49</label><mixed-citation publication-type="journal"><name><surname>Bose</surname><given-names>M</given-names></name>, <name><surname>Wu</surname><given-names>C</given-names></name>, <name><surname>Pankow</surname><given-names>JS</given-names></name>, <name><surname>Demerath</surname><given-names>EW</given-names></name>, <name><surname>Bressler</surname><given-names>J</given-names></name>, <name><surname>Fornage</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Evaluation of microarray-based DNA methylation measurement using technical replicates: the Atherosclerosis Risk In Communities (ARIC) Study</article-title>. <source>BMC Bioinformatics</source>. <year>2014</year>;<volume>15</volume>: <fpage>312</fpage>
<pub-id pub-id-type="doi">10.1186/1471-2105-15-312</pub-id>
<?supplied-pmid 25239148?><pub-id pub-id-type="pmid">25239148</pub-id></mixed-citation></ref><ref id="pone.0204371.ref050"><label>50</label><mixed-citation publication-type="journal"><name><surname>Skorodumova</surname><given-names>L</given-names></name>, <name><surname>Babalyan</surname><given-names>K</given-names></name>, <name><surname>Sultanov</surname><given-names>R</given-names></name>, <name><surname>Vasiliev</surname><given-names>AO</given-names></name>, <name><surname>Govorov</surname><given-names>A V</given-names></name>., <name><surname>Pushkar</surname><given-names>DY</given-names></name>, <etal>et al</etal>
<article-title>The methylation status of GSTP1, APC, and RASSF1 genes in human prostate cancer samples: Comparative analysis of diagnostic informativeness of MS-HRM and hybridization on the Illumina Infinium HumanMethylation450 BeadChip</article-title>. <source>Biochem Moscow Suppl Ser.</source>
<year>2017</year>;<volume>11</volume>: <fpage>194</fpage>.</mixed-citation></ref><ref id="pone.0204371.ref051"><label>51</label><mixed-citation publication-type="journal"><name><surname>Bock</surname><given-names>C</given-names></name>, <name><surname>Halbritter</surname><given-names>F</given-names></name>, <name><surname>Carmona</surname><given-names>FJ</given-names></name>, <name><surname>Tierling</surname><given-names>S</given-names></name>, <name><surname>Datlinger</surname><given-names>P</given-names></name>, <name><surname>Assenov</surname><given-names>Y</given-names></name>, <etal>et al</etal>
<article-title>Quantitative comparison of DNA methylation assays for biomarker development and clinical applications</article-title>. <source>Nat Biotechnol</source>. <year>2016</year>;<volume>34</volume>: <fpage>726</fpage>&#x02013;<lpage>737</lpage>. <pub-id pub-id-type="doi">10.1038/nbt.3605</pub-id>
<?supplied-pmid 27347756?><pub-id pub-id-type="pmid">27347756</pub-id></mixed-citation></ref><ref id="pone.0204371.ref052"><label>52</label><mixed-citation publication-type="journal"><name><surname>Cornford</surname><given-names>P</given-names></name>, <name><surname>Evans</surname><given-names>J</given-names></name>, <name><surname>Dodson</surname><given-names>a</given-names></name>, <name><surname>Parsons</surname><given-names>K</given-names></name>, <name><surname>Woolfenden</surname><given-names>a</given-names></name>, <name><surname>Neoptolemos</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Protein kinase C isoenzyme patterns characteristically modulated in early prostate cancer</article-title>. <source>Am J Pathol</source>. American Society for Investigative Pathology; <year>1999</year>;<volume>154</volume>: <fpage>137</fpage>&#x02013;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1016/S0002-9440(10)65260-1</pub-id>
<?supplied-pmid 9916928?><pub-id pub-id-type="pmid">9916928</pub-id></mixed-citation></ref><ref id="pone.0204371.ref053"><label>53</label><mixed-citation publication-type="journal"><name><surname>Yao</surname><given-names>S</given-names></name>, <name><surname>Ireland</surname><given-names>SJ</given-names></name>, <name><surname>Bee</surname><given-names>A</given-names></name>, <name><surname>Beesley</surname><given-names>C</given-names></name>, <name><surname>Forootan</surname><given-names>SS</given-names></name>, <name><surname>Dodson</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Splice variant PRKC-&#x003b6;-PrC is a novel biomarker of human prostate cancer</article-title>. <source>Br J Cancer</source>. <year>2012</year>;<volume>107</volume>: <fpage>388</fpage>&#x02013;<lpage>399</lpage>. <pub-id pub-id-type="doi">10.1038/bjc.2012.162</pub-id>
<?supplied-pmid 22644296?><pub-id pub-id-type="pmid">22644296</pub-id></mixed-citation></ref><ref id="pone.0204371.ref054"><label>54</label><mixed-citation publication-type="journal"><name><surname>Adeola</surname><given-names>HA</given-names></name>, <name><surname>Smith</surname><given-names>M</given-names></name>, <name><surname>Kaestner</surname><given-names>L</given-names></name>, <name><surname>Blackburn</surname><given-names>JM</given-names></name>, <name><surname>Zerbini</surname><given-names>LF</given-names></name>. <article-title>Novel potential serological prostate cancer biomarkers using CT100+ cancer antigen microarray platform in a multi-cultural South African cohort</article-title>. <source>Oncotarget</source>. <year>2016</year>;<volume>7</volume>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.18632/oncotarget.7359">10.18632/oncotarget.7359</ext-link></comment>
<?supplied-pmid 26885621?><pub-id pub-id-type="pmid">26885621</pub-id></mixed-citation></ref><ref id="pone.0204371.ref055"><label>55</label><mixed-citation publication-type="journal"><name><surname>Zou</surname><given-names>L</given-names></name>, <name><surname>Yan</surname><given-names>S</given-names></name>, <name><surname>Guan</surname><given-names>X</given-names></name>, <name><surname>Pan</surname><given-names>Y</given-names></name>, <name><surname>Qu</surname><given-names>X</given-names></name>. <article-title>Hypermethylation of the PRKCZ Gene in Type 2 Diabetes Mellitus</article-title>. <source>J Diabetes Res</source>. <year>2013</year>;<volume>2013</volume>: <fpage>721493</fpage>
<pub-id pub-id-type="doi">10.1155/2013/721493</pub-id>
<?supplied-pmid 23671888?><pub-id pub-id-type="pmid">23671888</pub-id></mixed-citation></ref><ref id="pone.0204371.ref056"><label>56</label><mixed-citation publication-type="journal"><name><surname>Aslibekyan</surname><given-names>S</given-names></name>, <name><surname>Dashti</surname><given-names>HS</given-names></name>, <name><surname>Tanaka</surname><given-names>T</given-names></name>, <name><surname>Sha</surname><given-names>J</given-names></name>, <name><surname>Ferrucci</surname><given-names>L</given-names></name>, <name><surname>Zhi</surname><given-names>D</given-names></name>, <etal>et al</etal>
<article-title>PRKCZ methylation is associated with sunlight exposure in a North American but not a Mediterranean population</article-title>. <source>Chronobiol Int</source>. <year>2014</year>;<volume>31</volume>: <fpage>1034</fpage>&#x02013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.3109/07420528.2014.944266</pub-id>
<?supplied-pmid 25075435?><pub-id pub-id-type="pmid">25075435</pub-id></mixed-citation></ref><ref id="pone.0204371.ref057"><label>57</label><mixed-citation publication-type="journal"><name><surname>Almeida</surname><given-names>M</given-names></name>, <name><surname>Costa</surname><given-names>VL</given-names></name>, <name><surname>Costa</surname><given-names>NR</given-names></name>, <name><surname>Ramalho-Carvalho</surname><given-names>J</given-names></name>, <name><surname>Baptista</surname><given-names>T</given-names></name>, <name><surname>Ribeiro</surname><given-names>FR</given-names></name>, <etal>et al</etal>
<article-title>Epigenetic regulation of EFEMP1 in prostate cancer: Biological relevance and clinical potential</article-title>. <source>J Cell Mol Med</source>. <year>2014</year>;<volume>18</volume>: <fpage>2287</fpage>&#x02013;<lpage>2297</lpage>. <pub-id pub-id-type="doi">10.1111/jcmm.12394</pub-id>
<?supplied-pmid 25211630?><pub-id pub-id-type="pmid">25211630</pub-id></mixed-citation></ref><ref id="pone.0204371.ref058"><label>58</label><mixed-citation publication-type="journal"><name><surname>Vanaja</surname><given-names>DK</given-names></name>, <name><surname>Ehrich</surname><given-names>M</given-names></name>, <name><surname>Boom</surname><given-names>D Van Den</given-names></name>, <name><surname>Cheville</surname><given-names>JC</given-names></name>, <name><surname>Karnes</surname><given-names>J</given-names></name>, <name><surname>Tindall</surname><given-names>DJ</given-names></name>, <etal>et al</etal>
<article-title>Hypermethylation of Genes for Diagnosis and Risk Stratification of Prostate Cancer</article-title>. <year>2009</year>;<volume>27</volume>: <fpage>549</fpage>&#x02013;<lpage>560</lpage>. <pub-id pub-id-type="doi">10.1080/07357900802620794</pub-id>
<?supplied-pmid 19229700?><pub-id pub-id-type="pmid">19229700</pub-id></mixed-citation></ref><ref id="pone.0204371.ref059"><label>59</label><mixed-citation publication-type="journal"><name><surname>Sertkaya</surname><given-names>S</given-names></name>, <name><surname>Hamid</surname><given-names>SM</given-names></name>, <name><surname>Dilsiz</surname><given-names>N</given-names></name>, <name><surname>Varisli</surname><given-names>L</given-names></name>. <article-title>Decreased expression of EFS is correlated with the advanced prostate cancer</article-title>. <source>Tumor Biol</source>. <year>2015</year>;<volume>36</volume>: <fpage>799</fpage>&#x02013;<lpage>805</lpage>. <pub-id pub-id-type="doi">10.1007/s13277-014-2703-5</pub-id>
<?supplied-pmid 25296736?><pub-id pub-id-type="pmid">25296736</pub-id></mixed-citation></ref><ref id="pone.0204371.ref060"><label>60</label><mixed-citation publication-type="journal"><name><surname>Lin</surname><given-names>P-C</given-names></name>, <name><surname>Giannopoulou</surname><given-names>EG</given-names></name>, <name><surname>Park</surname><given-names>K</given-names></name>, <name><surname>Mosquera</surname><given-names>JM</given-names></name>, <name><surname>Sboner</surname><given-names>A</given-names></name>, <name><surname>Tewari</surname><given-names>AK</given-names></name>, <etal>et al</etal>
<article-title>Epigenomic Alterations in Localized and Advanced Prostate Cancer</article-title>. <source>Neoplasia</source>. Neoplasia Press Inc; <year>2013</year>;<volume>15</volume>: <fpage>373</fpage>&#x02013;<lpage>IN5</lpage>. <pub-id pub-id-type="doi">10.1593/neo.122146</pub-id>
<?supplied-pmid 23555183?><pub-id pub-id-type="pmid">23555183</pub-id></mixed-citation></ref><ref id="pone.0204371.ref061"><label>61</label><mixed-citation publication-type="journal"><name><surname>Brikun</surname><given-names>I</given-names></name>, <name><surname>Nusskern</surname><given-names>D</given-names></name>, <name><surname>Gillen</surname><given-names>D</given-names></name>, <name><surname>Lynn</surname><given-names>A</given-names></name>, <name><surname>Murtagh</surname><given-names>D</given-names></name>, <name><surname>Feczko</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>A panel of DNA methylation markers reveals extensive methylation in histologically benign prostate biopsy cores from cancer patients</article-title>. <source>Biomark Res</source>. <year>2014</year>;<volume>2</volume>: <fpage>25</fpage>
<pub-id pub-id-type="doi">10.1186/s40364-014-0025-9</pub-id>
<?supplied-pmid 25548652?><pub-id pub-id-type="pmid">25548652</pub-id></mixed-citation></ref><ref id="pone.0204371.ref062"><label>62</label><mixed-citation publication-type="journal"><name><surname>Dai</surname><given-names>W</given-names></name>, <name><surname>Teodoridis</surname><given-names>JM</given-names></name>, <name><surname>Zeller</surname><given-names>C</given-names></name>, <name><surname>Graham</surname><given-names>J</given-names></name>, <name><surname>Hersey</surname><given-names>J</given-names></name>, <name><surname>Flanagan</surname><given-names>JM</given-names></name>, <etal>et al</etal>
<article-title>Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival</article-title>. <source>Clin Cancer Res</source>. <year>2011</year>;<volume>17</volume>: <fpage>4052</fpage>&#x02013;<lpage>4062</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-10-3021</pub-id>
<?supplied-pmid 21459799?><pub-id pub-id-type="pmid">21459799</pub-id></mixed-citation></ref><ref id="pone.0204371.ref063"><label>63</label><mixed-citation publication-type="journal"><name><surname>Kok-Sin</surname><given-names>T</given-names></name>, <name><surname>Mokhtar</surname><given-names>NM</given-names></name>, <name><surname>Hassan</surname><given-names>NZA</given-names></name>, <name><surname>Sagap</surname><given-names>I</given-names></name>, <name><surname>Rose</surname><given-names>IM</given-names></name>, <name><surname>Harun</surname><given-names>R</given-names></name>, <etal>et al</etal>
<article-title>Identification of diagnostic markers in colorectal cancer via integrative epigenomics and genomics data</article-title>. <source>Oncol Rep</source>. <year>2015</year>;<volume>34</volume>: <fpage>22</fpage>&#x02013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.3892/or.2015.3993</pub-id>
<?supplied-pmid 25997610?><pub-id pub-id-type="pmid">25997610</pub-id></mixed-citation></ref><ref id="pone.0204371.ref064"><label>64</label><mixed-citation publication-type="journal"><name><surname>&#x000d8;ster</surname><given-names>B</given-names></name>, <name><surname>Thorsen</surname><given-names>K</given-names></name>, <name><surname>Lamy</surname><given-names>P</given-names></name>, <name><surname>Wojdacz</surname><given-names>TK</given-names></name>, <name><surname>Hansen</surname><given-names>LL</given-names></name>, <name><surname>Birkenkamp-Demtr&#x000f6;der</surname><given-names>K</given-names></name>, <etal>et al</etal>
<article-title>Identification and validation of highly frequent CpG island hypermethylation in colorectal adenomas and carcinomas</article-title>. <source>Int J Cancer</source>. <year>2011</year>;<volume>129</volume>: <fpage>2855</fpage>&#x02013;<lpage>2866</lpage>. <pub-id pub-id-type="doi">10.1002/ijc.25951</pub-id>
<?supplied-pmid 21400501?><pub-id pub-id-type="pmid">21400501</pub-id></mixed-citation></ref><ref id="pone.0204371.ref065"><label>65</label><mixed-citation publication-type="journal"><name><surname>Naumov</surname><given-names>VA</given-names></name>, <name><surname>Generozov</surname><given-names>E V</given-names></name>., <name><surname>Zaharjevskaya</surname><given-names>NB</given-names></name>, <name><surname>Matushkina</surname><given-names>DS</given-names></name>, <name><surname>Larin</surname><given-names>AK</given-names></name>, <name><surname>Chernyshov</surname><given-names>S V</given-names></name>., <etal>et al</etal>
<article-title>Genome-scale analysis of DNA methylation in colorectal cancer using Infinium HumanMethylation450 BeadChips</article-title>. <source>Epigenetics</source>. <year>2013</year>;<volume>8</volume>: <fpage>921</fpage>&#x02013;<lpage>934</lpage>. <pub-id pub-id-type="doi">10.4161/epi.25577</pub-id>
<?supplied-pmid 23867710?><pub-id pub-id-type="pmid">23867710</pub-id></mixed-citation></ref><ref id="pone.0204371.ref066"><label>66</label><mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>F</given-names></name>, <name><surname>Huang</surname><given-names>T</given-names></name>, <name><surname>Ren</surname><given-names>Y</given-names></name>, <name><surname>Wei</surname><given-names>J</given-names></name>, <name><surname>Lou</surname><given-names>Z</given-names></name>, <name><surname>Wang</surname><given-names>X</given-names></name>, <etal>et al</etal>
<article-title>Clinical significance of CDH13 promoter methylation as a biomarker for bladder cancer: a meta-analysis</article-title>. <source>BMC Urol</source>. BMC Urology; <year>2016</year>;<volume>16</volume>: <fpage>52</fpage>
<pub-id pub-id-type="doi">10.1186/s12894-016-0171-5</pub-id>
<?supplied-pmid 27578166?><pub-id pub-id-type="pmid">27578166</pub-id></mixed-citation></ref><ref id="pone.0204371.ref067"><label>67</label><mixed-citation publication-type="journal"><name><surname>Dammann</surname><given-names>R</given-names></name>, <name><surname>Strunnikova</surname><given-names>M</given-names></name>, <name><surname>Schagdarsurengin</surname><given-names>U</given-names></name>, <name><surname>Rastetter</surname><given-names>M</given-names></name>, <name><surname>Papritz</surname><given-names>M</given-names></name>, <name><surname>Hattenhorst</surname><given-names>UE</given-names></name>, <etal>et al</etal>
<article-title>CpG island methylation and expression of tumour-associated genes in lung carcinoma</article-title>. <source>Eur J Cancer</source>. <year>2005</year>;<volume>41</volume>: <fpage>1223</fpage>&#x02013;<lpage>1236</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejca.2005.02.020</pub-id>
<?supplied-pmid 15911247?><pub-id pub-id-type="pmid">15911247</pub-id></mixed-citation></ref><ref id="pone.0204371.ref068"><label>68</label><mixed-citation publication-type="journal"><name><surname>Mori</surname><given-names>Y</given-names></name>, <name><surname>Cai</surname><given-names>K</given-names></name>, <name><surname>Cheng</surname><given-names>Y</given-names></name>, <name><surname>Wang</surname><given-names>S</given-names></name>, <name><surname>Paun</surname><given-names>B</given-names></name>, <name><surname>Hamilton</surname><given-names>JP</given-names></name>, <etal>et al</etal>
<article-title>A Genome-Wide Search Identifies Epigenetic Silencing of Somatostatin, Tachykinin-1, and 5 Other Genes in Colon Cancer</article-title>. <source>Gastroenterology</source>. <year>2006</year>;<volume>131</volume>: <fpage>797</fpage>&#x02013;<lpage>808</lpage>. <pub-id pub-id-type="doi">10.1053/j.gastro.2006.06.006</pub-id>
<?supplied-pmid 16952549?><pub-id pub-id-type="pmid">16952549</pub-id></mixed-citation></ref><ref id="pone.0204371.ref069"><label>69</label><mixed-citation publication-type="journal"><name><surname>Henry</surname><given-names>L a</given-names></name>, <name><surname>Johnson</surname><given-names>D a</given-names></name>, <name><surname>Sarri&#x000f3;</surname><given-names>D</given-names></name>, <name><surname>Lee</surname><given-names>S</given-names></name>, <name><surname>Quinlan</surname><given-names>PR</given-names></name>, <name><surname>Crook</surname><given-names>T</given-names></name>, <etal>et al</etal>
<article-title>Endoglin expression in breast tumor cells suppresses invasion and metastasis and correlates with improved clinical outcome</article-title>. <source>Oncogene</source>. <year>2011</year>;<volume>30</volume>: <fpage>1046</fpage>&#x02013;<lpage>1058</lpage>. <pub-id pub-id-type="doi">10.1038/onc.2010.488</pub-id>
<?supplied-pmid 21042283?><pub-id pub-id-type="pmid">21042283</pub-id></mixed-citation></ref></ref-list></back></article>